API




KE Relationships

Navigational tip: click on "leads to" or the ID column to navigate to the KE Relationship.
Id Upstream Event Relationship Type Downstream Event
5 Reduction, 17beta-estradiol synthesis by ovarian granulosa cells leads to Reduction, Plasma 17beta-estradiol concentrations
9 Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity leads to Decreased, Mitochondrial fatty acid beta-oxidation
11 AchE Inhibition leads to ACh Synaptic Accumulation
16 Altered regulation, AHR nuclear translocator (ARNT)-dependent pathways leads to Altered, Cardiovascular development/function
17 Altered regulation, AHR nuclear translocator (ARNT)-dependent pathways leads to Up Regulation, CYP1A1
18 Activation, AhR leads to Altered regulation, AHR nuclear translocator (ARNT)-dependent pathways
19 Activation, AhR leads to Up Regulation, CYP1A1
23 Alkylation, DNA leads to Increase, Heritable mutations in offspring
24 Alkylation, DNA leads to N/A, Inadequate DNA repair
25 Alkylation, DNA leads to Increase, Mutations
31 Agonism, Androgen receptor leads to Reduction, Gonadotropins, circulating concentrations
32 Agonism, Androgen receptor leads to Reduction, Testosterone synthesis by ovarian theca cells
33 N/A, Androgen receptor, Antagonism leads to Decreased, Transcription of genes by AR
35 N/A, Androgen receptor, Antagonism leads to Alteration, Wnt pathway
36 Reduction, Angiogenesis leads to Impairment, Endothelial network
43 Decrease, Aromatase (Cyp19a1) leads to Reduction, 17beta-estradiol synthesis by ovarian granulosa cells
45 Inhibition, Aromatase leads to Reduction, 17beta-estradiol synthesis by ovarian granulosa cells
51 Increased Cholinergic Signaling leads to Decrease, Population trajectory
59 Reduction, Ca and HCO3 transport to shell gland leads to Reduction, Eggshell thickness
60 Increase, Ca++ (intracellular) leads to Disruption, Mitochondrial electron transport chain
61 Inhibition, Ca++ ATPase leads to Increase, Ca++ (intracellular)
62 Decreased, Calcium influx leads to Impairment, Learning and memory
66 Up Regulation, CD36 leads to Increase, FA Influx
67 Cell injury/death leads to Increased, Activation and Recruitment of Hepatic macrophages (Kupffer Cells)
68 Cell injury/death leads to Activation, Stellate cells
69 Proliferation, Cell proliferation in the absence of cytotoxicity leads to Hyperplasia, Hyperplasia
70 Induction, Chitin degradation and resorption leads to Induction, Pre-mature molting
77 Activation, ChREBP leads to Synthesis, De Novo FA
82 Accumulation, Collagen leads to N/A, Liver fibrosis
88 N/A, Covalent binding to protein, possibly lysine residue leads to Activation, Inflammatory cytokines, chemokines, cytoprotective gene pathways
93 Production, Critical Metabolites (CGA 330050 and CGA 265307) leads to Induction, Liver “Dysfunctional” Changes by CGA 330050
94 Reduction, Cumulative fecundity and spawning leads to Decrease, Population trajectory
95 Inhibition, Cyclooxygenase activity leads to Reduction, Prostaglandin E2 concentration
96 Up Regulation, CYP1A1 leads to Peptide Oxidation
104 Up Regulation, CYP1B1 leads to Reduction, 17beta-estradiol synthesis by ovarian granulosa cells
108 Release, Cytokine leads to Increase, Inflammation
110 Synthesis, De Novo FA leads to Accumulation, Triglyceride
116 Increase, EcR agonism leads to Induction, Chitin degradation and resorption
123 Reduction, Eggshell thickness leads to N/A, Reproductive failure
125 Impairment, Endothelial network leads to Insufficiency, Vascular
126 Agonism, Estrogen receptor leads to Altered, Reproductive behaviour
127 Agonism, Estrogen receptor leads to Impaired development of, Reproductive organs
128 Agonism, Estrogen receptor leads to Increase, Vitellogenin synthesis in liver
129 Antagonism, Estrogen receptor leads to Reduction, Vitellogenin synthesis in liver
132 Increase, FA Influx leads to Accumulation, Triglyceride
133 Activation, FAS leads to Synthesis, De Novo FA
135 Decrease, Fecundity leads to Decline, Population
136 N/A, Gap leads to Reduction, Ca and HCO3 transport to shell gland
143 Reduction, Gonadotropins, circulating concentrations leads to Reduction, Testosterone synthesis by ovarian theca cells
144 Depletion, GSH leads to N/A, Oxidative stress
146 Increased, Activation and Recruitment of Hepatic macrophages (Kupffer Cells) leads to Peptide Oxidation
147 Increased, Activation and Recruitment of Hepatic macrophages (Kupffer Cells) leads to Up Regulation, TGFbeta1 expression
154 Decreased, HSD17B10 expression leads to Decreased, 3-hydroxyacyl-CoA dehydrogenase type-2 activity
158 Hyperplasia, Hyperplasia leads to Promotion, Hepatocelluar carcinoma
159 Inhibition, Inducible Nitric Oxide Synthase by Metabolite CGA 265307 leads to Induction, Sustained Hepatotoxicity
164 N/A, Inadequate DNA repair leads to Increase, Mutations
168 N/A, Interferences with SH-/selen-proteins leads to Depletion, GSH
169 Increase, Liver and splenic hemosiderosis leads to N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number
170 Induction, Liver “Dysfunctional” Changes by CGA 330050 leads to Inhibition, Inducible Nitric Oxide Synthase by Metabolite CGA 265307
172 Activation, Long term AHR receptor driven direct and indirect gene expression changes leads to N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects
173 Activation, LXR leads to Up Regulation, CD36
174 Activation, LXR leads to Activation, ChREBP
175 Activation, LXR leads to Activation, FAS
176 Activation, LXR leads to Activation, SCD-1
177 Activation, LXR leads to Activation, SREBP-1c
182 N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number leads to N/A, Cyanosis occurs
188 Disruption, Mitochondrial electron transport chain leads to Decrease, Mitochondrial ATP production
189 Disruption, Mitochondrial electron transport chain leads to Increase, ROS production
190 Decreased, Mitochondrial fatty acid beta-oxidation leads to Accumulation, Fatty acid
196 Abnormal, Morphogenesis leads to Increased, Lethality
197 Abnormal, Morphogenesis leads to Increased, Structural malformations
198 Increase, Mortality leads to Decrease, Fecundity
199 Increase, Mortality leads to Decline, Population
200 Increased Mortality leads to Decline, Population
202 Increase, Mutations leads to Increase, Heritable mutations in offspring
203 Altered, Neuroanatomy leads to Altered, Neurophysiology
207 N/A, Neurodegeneration leads to Neuroinflammation
208 Neuroinflammation leads to N/A, Neurodegeneration
210 N/A, Neuronal dysfunction leads to Neuroinflammation
212 Decreased, Nitric Oxide leads to Decreased, Long-term potentiation (LTP)
213 Inhibition, NMDARs leads to Decreased, Calcium influx
214 Inhibition, NMDARs leads to Impairment, Learning and memory
215 Inhibition, NMDARs leads to N/A, Neuronal dysfunction
228 Binding of antagonist, NMDA receptors leads to Impairment, Learning and memory
229 Binding of antagonist, NMDA receptors leads to Inhibition, NMDARs
236 Peptide Oxidation leads to Increased, Activation and Recruitment of Hepatic macrophages (Kupffer Cells)
239 N/A, Oxidative stress leads to N/A, Neuronal dysfunction
240 Propagation, Oxidative stress leads to Down Regulation, Gulcose-6-phosphate dehydrogenase
241 Propagation, Oxidative stress leads to Damaging, Red blood cells; hemolysis
242 N/A, Parent compound is converted to the reactive metabolite and forms free radicals leadin leads to Altered regulation, Alpha hemoglobin
243 N/A, Parent compound is converted to the reactive metabolite and forms free radicals leadin leads to Formation, Formation of hemoglobin adducts
244 N/A, Parent compound is converted to the reactive metabolite and forms free radicals leadin leads to Propagation, Oxidative stress
245 N/A, Parent compound is converted to the reactive metabolite and forms free radicals leadin leads to Damaging, Red blood cells; hemolysis
248 Bile accumulation, Pathological condition leads to Activation of specific nuclear receptors, Transcriptional change
252 Reduction, Plasma 17beta-estradiol concentrations leads to Reduction, Vitellogenin synthesis in liver
253 Reduction, Plasma 17beta-estradiol concentrations leads to Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development
254 Increase, Plasma vitellogenin concentrations leads to Increase, Renal pathology due to VTG deposition
255 Reduction, Plasma vitellogenin concentrations leads to Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development
256 demethylation, PPARg promoter leads to Decrease, Aromatase (Cyp19a1)
257 Decreased, PPAR-alpha activation leads to Decreased, HSD17B10 expression
259 Decreased, PPAR-beta activation leads to Decreased, HSD17B10 expression
260 Decreased, PPAR-gamma activation leads to Decreased, HSD17B10 expression
261 Induction, Pre-mature molting leads to Decrease, Fecundity
262 Induction, Pre-mature molting leads to Increase, Mortality
263 Induction, Pre-mature molting leads to Increased Mortality
266 Feminisation or incomplete development, Primary and accessory male sex organs leads to N/A, Impairment of reproductive capacity
268 Reduction, Prostaglandin E2 concentration leads to N/A, Gap
269 Alkylation, Protein leads to Cell injury/death
271 Alkylation, Protein leads to Peptide Oxidation
272 Increase, RBC congestion in liver leads to N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number
276 Production, Reactive oxygen species leads to Peptide Oxidation
277 Damaging, Red blood cells; hemolysis leads to Increase, Liver and splenic hemosiderosis
278 Damaging, Red blood cells; hemolysis leads to N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number
279 Damaging, Red blood cells; hemolysis leads to Increase, RBC congestion in liver
280 Increase, Renal pathology due to VTG deposition leads to Altered, Larval development
282 Increase, ROS production leads to Decreased, Nitric Oxide
283 Increase, ROS production leads to Increased, Oxidative damage
284 Activation, SCD-1 leads to Synthesis, De Novo FA
287 Binding, SH-/selen-proteins leads to N/A, Interferences with SH-/selen-proteins
294 Activation, SREBP-1c leads to Synthesis, De Novo FA
295 Activation, Stellate cells leads to Accumulation, Collagen
296 Increased, Structural malformations leads to Increased, Lethality
298 Induction, Sustained Cell Proliferation leads to Formation, Liver tumor
299 Induction, Sustained Hepatotoxicity leads to Induction, Sustained Cell Proliferation
301 Activation/Proliferation, T-cells leads to N/A, Allergic contact dermatitis on challenge
302 Reduction, Testosterone synthesis by ovarian theca cells leads to Reduction, 17beta-estradiol synthesis by ovarian granulosa cells
303 Up Regulation, TGFbeta1 expression leads to Accumulation, Collagen
304 Up Regulation, TGFbeta1 expression leads to Activation, Stellate cells
305 TH synthesis, Decreased leads to T4 in serum, Decreased
309 Thyroperoxidase, Inhibition leads to TH synthesis, Decreased
312 T4 in serum, Decreased leads to T4 in neuronal tissue, Decreased
315 Reduction, Vitellogenin synthesis in liver leads to Reduction, Plasma vitellogenin concentrations
316 Decreased, Transcription of genes by AR leads to Feminisation or incomplete development, Primary and accessory male sex organs
317 Decreased, Transcription of genes by AR leads to Alteration, Wnt pathway
319 Activation of specific nuclear receptors, Transcriptional change leads to Cholestasis, Pathology
321 Accumulation, Triglyceride leads to Damaging, Mitochondria
324 N/A, Unknown leads to Proliferation, Cell proliferation in the absence of cytotoxicity
329 Insufficiency, Vascular leads to Abnormal, Morphogenesis
330 Binding, VEGF-A leads to Decreased, VegfR2
331 Binding, VEGF-A leads to Inhibition, VegfR2
332 Production, VEGF-A leads to Binding, VEGF-A
333 Production, VEGF-A leads to Decreased, VegfR2
334 Decreased, VegfR2 leads to Inhibition, VegfR2
335 Inhibition, VegfR2 leads to Reduction, Angiogenesis
336 Increase, Vitellogenin synthesis in liver leads to Increase, Plasma vitellogenin concentrations
337 Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development leads to Reduction, Cumulative fecundity and spawning
338 Alteration, Wnt pathway leads to Feminisation or incomplete development, Primary and accessory male sex organs
340 Activation, Pre-MIE: Metabolism of AFB1 leads to Formation, Pro-mutagenic DNA Adducts
342 Increased, Induced Mutations in Critical Genes leads to Increased, Proliferation/Clonal Expansion of Mutant Cells (Pre-Neoplastic Lesions/Altered H
343 Increased, Proliferation/Clonal Expansion of Mutant Cells (Pre-Neoplastic Lesions/Altered H leads to Tumorigenesis, Hepatocellular carcinoma
344 Formation, Pro-mutagenic DNA Adducts leads to Increased, Proliferation/Clonal Expansion of Mutant Cells (Pre-Neoplastic Lesions/Altered H
345 Formation, Pro-mutagenic DNA Adducts leads to Tumorigenesis, Hepatocellular carcinoma
346 Increased, Induced Mutations in Critical Genes leads to Tumorigenesis, Hepatocellular carcinoma
347 Decreased, Calcium influx leads to BDNF, Reduced
348 BDNF, Reduced leads to Aberrant, Dendritic morphology
350 Increased, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci leads to Tumorigenesis, Hepatocellular carcinoma
351 Increased, Induced Mutations in Critical Genes leads to Increased, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci
352 Formation, Pro-mutagenic DNA Adducts leads to Increased, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci
353 BDNF, Reduced leads to Cell injury/death
354 BDNF, Reduced leads to Reduced, Presynaptic release of glutamate
355 Cell injury/death leads to Synaptogenesis, Decreased
356 Aberrant, Dendritic morphology leads to Synaptogenesis, Decreased
357 Reduced, Presynaptic release of glutamate leads to Synaptogenesis, Decreased
358 Synaptogenesis, Decreased leads to Neuronal network function, Decreased
359 Neuronal network function, Decreased leads to Impairment, Learning and memory
360 Binding of agonist, NMDARs leads to Overactivation, NMDARs
361 Overactivation, NMDARs leads to Increased, Intracellular Calcium overload
362 Increased, Intracellular Calcium overload leads to N/A, Mitochondrial dysfunction 1
363 N/A, Mitochondrial dysfunction 1 leads to Cell injury/death
364 Cell injury/death leads to N/A, Neurodegeneration
365 Cell injury/death leads to Neuroinflammation
366 Thyroperoxidase, Inhibition leads to T4 in serum, Decreased
368 N/A, Neurodegeneration leads to Neuronal network function, Decreased
369 Activation, PPARα leads to Decrease, Steroidogenic acute regulatory protein (STAR)
370 Activation, PPARα leads to Decrease, Translocator protein (TSPO)
376 Covalent Binding, Protein leads to Response, Keratinocytes
377 Covalent Binding, Protein leads to Activation, Dendritic Cells
378 Response, Keratinocytes leads to Activation, Dendritic Cells
379 Activation, Dendritic Cells leads to Activation/Proliferation, T-cells
380 Response, Keratinocytes leads to Activation/Proliferation, T-cells
383 Thyroperoxidase, Inhibition leads to Cognitive Function, Decreased
384 Altered, Neurophysiology leads to Cognitive Function, Decreased
385 Activation, Glucocorticoid Receptor leads to Induction, IKB inhibitory protein
386 Induction, IKB inhibitory protein leads to Inhibition, Nuclear factor kappa B (NF-kB)
387 Inhibition, Nuclear factor kappa B (NF-kB) leads to Suppression, Inflammatory cytokines
388 Suppression, Inflammatory cytokines leads to Decreased, Lymphocytes
389 Decreased, Lymphocytes leads to Increased, Disease susceptibility
390 Decreased, Lymphocytes leads to Suppression, Immune system
392 Reduction, Plasma 17beta-estradiol concentrations leads to irregularities, ovarian cycle
393 irregularities, ovarian cycle leads to Decrease, Fertility
394 irregularities, ovarian cycle leads to impaired, Fertility
395 demethylation, PPARg promoter leads to reduction in ovarian granulosa cells, Aromatase (Cyp19a1)
396 reduction in ovarian granulosa cells, Aromatase (Cyp19a1) leads to Reduction, 17beta-estradiol synthesis by ovarian granulosa cells
398 Increase proliferation, Leydig cell leads to Hyperplasia, Leydig cell
399 Decrease, Translocator protein (TSPO) leads to Reduction, Testosterone synthesis in Leydig cells
402 Metabolism of AFB1, Production of Reactive Electrophiles leads to Formation, Pro-mutagenic DNA Adducts
403 T4 in serum, Decreased leads to Cognitive Function, Decreased
405 Malformation, Male reproductive tract leads to impaired, Fertility
411 demethylation, PPARg promoter leads to Up Regulation, CD36
428 Increased Mortality leads to Decreased, Population trajectory
432 Increased, Atrioventricular block and bradycardia leads to Increased Mortality
433 Respiratory distress/arrest leads to Increased Mortality
434 Increased Cholinergic Signaling leads to Increased Mortality
436 Decrease, Steroidogenic acute regulatory protein (STAR) leads to Reduction, Cholesterol transport in mitochondria
437 Decrease, Translocator protein (TSPO) leads to Reduction, Cholesterol transport in mitochondria
438 Reduction, Cholesterol transport in mitochondria leads to Reduction, Testosterone synthesis in Leydig cells
439 Reduction, Testosterone synthesis in Leydig cells leads to Reduction, testosterone level
442 Inhibition, Na+/I- symporter (NIS) leads to Thyroidal Iodide, Decreased
443 Thyroidal Iodide, Decreased leads to T4 in serum, Decreased
444 T4 in neuronal tissue, Decreased leads to BDNF, Reduced
445 BDNF, Reduced leads to Down Regulation, K-Cl co-transporter 2 (KCC2)
446 Down Regulation, K-Cl co-transporter 2 (KCC2) leads to Delay, Developmental GABA shift
447 Delay, Developmental GABA shift leads to Synaptogenesis, Decreased
448 BDNF, Reduced leads to Synaptogenesis, Decreased
449 AchE Inhibition leads to Increased, Atrioventricular block and bradycardia
450 AchE Inhibition leads to Respiratory distress/arrest
451 AchE Inhibition leads to Increased Cholinergic Signaling
452 AchE Inhibition leads to Increased Mortality
453 AchE Inhibition leads to Decreased, Population trajectory
454 ACh Synaptic Accumulation leads to Increased, Atrioventricular block and bradycardia
456 ACh Synaptic Accumulation leads to Increased Cholinergic Signaling
457 Increased Cholinergic Signaling leads to Respiratory distress/arrest
459 ACh Synaptic Accumulation leads to AchE Inhibition
460 Reduction, testosterone level leads to Increase, Luteinizing hormone (LH)
461 Increase, Luteinizing hormone (LH) leads to Increase proliferation, Leydig cell
462 Hyperplasia, Leydig cell leads to impaired, Fertility
470 Inhibition, Mitochondrial fatty acid beta-oxidation leads to Accumulation, Liver lipid
471 Suppression, VLDL secretion leads to Accumulation, Liver lipid
472 Accumulation, Fatty acid leads to Accumulation, Triglyceride
473 Activation, AhR leads to Inhibition, Mitochondrial fatty acid beta-oxidation
474 Accumulation, Triglyceride leads to Accumulation, Liver lipid
475 Inhibition, Mitochondrial fatty acid beta-oxidation leads to Accumulation, Fatty acid
476 Suppression, Constitutive androstane receptor, NR1l3 leads to Activation, LXR
477 Suppression, Constitutive androstane receptor, NR1l3 leads to demethylation, PPARg promoter
479 Activation, LXR leads to Activation, SREBF1
482 Activation, SREBF1 leads to Increased, De Novo FA synthesis
483 Activation, ChREBP leads to Increased, De Novo FA synthesis
484 Increased, De Novo FA synthesis leads to Increased, Triglyceride formation
486 Increased, Triglyceride formation leads to Increased, Liver Steatosis
487 demethylation, PPARg promoter leads to Activation, SREBF1
489 Activation, SREBF1 leads to Up Regulation, SCD-1
490 Activation, LXR leads to Up Regulation, FAS
491 Activation, LXR leads to Up Regulation, SCD-1
492 Up Regulation, FAS leads to Increased, De Novo FA synthesis
493 Up Regulation, SCD-1 leads to Increased, Triglyceride formation
495 Activation, AhR leads to Up Regulation, CD36
496 Activation, AhR leads to Increased, FA Influx
499 Activation, AhR leads to Decreased, PCK1 expression (control point for glycolysis/gluconeogenesis pathway)
501 Up Regulation, CD36 leads to Increased, FA Influx
502 Accumulation, Fatty acid leads to Accumulation, Liver lipid
503 Decreased, PCK1 expression (control point for glycolysis/gluconeogenesis pathway) leads to Accumulation, Fatty acid
504 Increased, FA Influx leads to Accumulation, Triglyceride
505 Increased, FA Influx leads to Accumulation, Fatty acid
506 Activation, AhR leads to Up Regulation, LDLR (low density lipoprotein receptor)
507 Up Regulation, LDLR (low density lipoprotein receptor) leads to Increased, LDL uptake
508 Increased, LDL uptake leads to Accumulation, Fatty acid
509 Activation, AhR leads to Suppression, VLDL secretion
510 Activation, LXR leads to Inhibition, PPAR alpha
511 Inhibition, PPAR alpha leads to Inhibition, Mitochondrial fatty acid beta-oxidation
512 Increased, De Novo FA synthesis leads to Accumulation, Fatty acid
514 Accumulation, Fatty acid leads to Increased, Triglyceride formation
515 Accumulation, Fatty acid leads to Increased, Liver Steatosis
516 Activation, LXR leads to Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1)
517 Up Regulation, Acetyl-CoA carboxylase-1 (ACC-1) leads to Increased, De Novo FA synthesis
518 Activation, PXR/SXR leads to Inhibition, FoxA2
519 Inhibition, FoxA2 leads to Down Regulation, CPT1A
520 Down Regulation, CPT1A leads to Decreased, Mitochondrial fatty acid beta-oxidation
523 Inhibition, FoxA2 leads to Down Regulation, HMGCS2
524 Down Regulation, HMGCS2 leads to Decreased, Ketogenesis
526 Activation, PXR/SXR leads to Up Regulation, SCD-1
529 Activation, PXR/SXR leads to Up Regulation, CD36
532 Activation, NRF2 leads to Activation, NR1H4
533 Activation, NR1H4 leads to Activation, SHP
534 Activation, NR1H4 leads to Activation, PPARα
535 Activation, PPARα leads to Activation, LXR alpha
537 Decreased, DHB4/HSD17B4 leads to Inhibition, Mitochondrial fatty acid beta-oxidation
538 Inhibition, Mitochondrial fatty acid beta-oxidation leads to Increased, Liver Steatosis
541 inflammation leads to Activation, AKT2
544 Decrease, Ovulation leads to Reduction, Cumulative fecundity and spawning
547 Increased, Insufficient repair or mis-repair of pro-mutagenic DNA adducts leads to Increased, Induced Mutations in Critical Genes
548 Formation, Pro-mutagenic DNA Adducts leads to Increased, Insufficient repair or mis-repair of pro-mutagenic DNA adducts
549 Increased, Induced Mutations in Critical Genes leads to Clonal Expansion/Cell Proliferation, to form Altered Hepatic Foci (AHF)
550 Clonal Expansion/Cell Proliferation, to form Altered Hepatic Foci (AHF) leads to Tumorigenesis, Hepatocellular carcinoma
551 Formation, Pro-mutagenic DNA Adducts leads to Clonal Expansion/Cell Proliferation, to form Altered Hepatic Foci (AHF)
552 Inhibition, Na+/I- symporter (NIS) leads to TH synthesis, Decreased
558 Reduced, Food storage leads to Decrease, Number of worker bees
559 Decrease, Number of worker bees leads to Death/Failure, Colony
562 Reduced, Food storage leads to impaired, Larval development
563 impaired, Larval development leads to Death/Failure, Colony
564 Impairment, Learning and memory leads to Abnormal, Roll change within caste
565 Abnormal, Roll change within caste leads to Reduced, Brood care
566 Reduced, Brood care leads to impaired, Larval development
567 Increase, Energetic demands and therefore metabolic stress leads to Increased, Appetite and hunger
568 Increased, Appetite and hunger leads to Abnormal, Foraging activity and behavior
569 Abnormal, Foraging activity and behavior leads to Decrease, Number of worker bees
570 Suppression, Immune system leads to Increased, Viral susceptibility
571 Increased, Viral susceptibility leads to impaired, Development
572 impaired, Development leads to Decrease, Number of worker bees
573 Decrease, Number of worker bees leads to impaired, Hive thermoregulation
574 impaired, Hive thermoregulation leads to Death/Failure, Colony
575 Increased, Viral susceptibility leads to Abnormal, Foraging activity and behavior
576 Decreased, Glucose oxidase enzyme activity leads to Decreased, Hydrogen peroxide production
577 Decreased, Hydrogen peroxide production leads to Reduced, Antiseptic incorporated in food
578 Reduced, Antiseptic incorporated in food leads to Abnormal, Roll change within caste
579 Abnormal, Roll change within caste leads to Reduced, Food storage
580 Abnormal, Roll change within caste leads to Decrease, Number of worker bees
581 Activation, Nicotinic acetylcholine receptor leads to N/A, Mitochondrial dysfunction 1
582 N/A, Mitochondrial dysfunction 1 leads to Neuronal network function, Decreased
583 Impairment, Learning and memory leads to Abnormal, Foraging activity and behavior
584 Abnormal, Foraging activity and behavior leads to Reduced, Food storage
585 Inhibition, sodium channel leads to Decreased, Sodium conductance 1
586 Decreased, Sodium conductance 1 leads to Reduced, swimming speed
587 Reduced, swimming speed leads to Reduced, feeding 1
588 Reduced, swimming speed leads to Increased, predation
589 Reduced, feeding 1 leads to Increased, predation
590 Inhibition, sodium channel leads to Increased, Atrioventricular block and bradycardia
591 Increased, Atrioventricular block and bradycardia leads to Respiratory distress/arrest
592 Respiratory distress/arrest leads to N/A, hypoxia
593 N/A, hypoxia leads to Increased, amputations
594 Decreased, Sodium conductance 1 leads to Increased, Atrioventricular block and bradycardia
595 Increased, predation leads to Reduced, survival
596 Reduced, feeding 1 leads to Reduced, survival
597 Inhibition, Ether-a-go-go (ERG) voltage-gated potassium channel leads to Decreased, Sodium conductance 1
603 modulation, sodium channel leads to prolonged, Depolarization of neuronal membrane
604 prolonged, Depolarization of neuronal membrane leads to Overactivation, Neuronotransmitter release
605 Overactivation, Neuronotransmitter release leads to Overactivation, muscle contraction
606 Overactivation, muscle contraction leads to Increased, Ataxia, paralysis, or hyperactivity
607 Increased, Ataxia, paralysis, or hyperactivity leads to Increased Mortality
608 Reduction, testosterone level leads to Malformation, Male reproductive tract
617 Decreased, Mitochondrial fatty acid beta-oxidation leads to Increased, Liver Steatosis
630 Occurrence, A paroxysmal depolarizing shift leads to Occurrence, Epileptic seizure
634 Decreased, Neuronal network function in adult brain leads to Impairment, Learning and memory
635 Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) leads to Increased, serotonin (5-HT) 1
636 Increased, serotonin (5-HT) 1 leads to Increase, cilia movement
637 Increase, cilia movement leads to Increased, locomotion
638 Increased, locomotion leads to Increase, predation
639 Increase, cilia movement leads to Increased, foot detachment
640 Increased, serotonin (5-HT) 1 leads to Increased, muscular waves in foot
641 Increased, muscular waves in foot leads to Increased, locomotion
642 Increased, muscular waves in foot leads to Increased, foot detachment
643 Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) leads to Increased, serotonin (5-HT)
644 Increased, serotonin (5-HT) leads to Decreased, anxiety
645 Decreased, anxiety leads to Decreased, sheltering
646 Decreased, sheltering leads to Increased, predation
647 N/A, Neurodegeneration leads to Decreased, Neuronal network function in adult brain
649 Decrease, histaminergic neuron excitation leads to N/A, sedation
650 N/A, sedation leads to Decreased, locomotion
651 Decreased, locomotion leads to Increased, predation
654 Increased, predation leads to Decreased, survival
656 Synaptogenesis, Decreased leads to Neuroinflammation
658 Activation, Nicotinic acetylcholine receptor leads to Desensitization, Nicotinic acetylcholine receptor
659 Desensitization, Nicotinic acetylcholine receptor leads to Neuronal network function, Decreased
660 N/A, Mitochondrial dysfunction 1 leads to Overwhelmed, Mitochondrial DNA repair mechanisms
661 Overwhelmed, Mitochondrial DNA repair mechanisms leads to Accumulation, Damaged mitochondrial DNA
662 Accumulation, Damaged mitochondrial DNA leads to Accelerated, Aging
663 Accelerated, Aging leads to Decrease, Number of worker bees
664 N/A, Mitochondrial dysfunction 1 leads to impaired, Thoracic shivering
665 impaired, Thoracic shivering leads to impaired, Hive thermoregulation
666 Binding at picrotoxin site, iGABAR chloride channel leads to Reduction, Ionotropic GABA receptor chloride channel conductance
667 Reduction, Ionotropic GABA receptor chloride channel conductance leads to Reduction, Neuronal synaptic inhibition
670 Inhibition, Cyclooxygenase activity leads to Reduced, Prostaglandin F2alpha synthesis, ovary
671 Reduced, Prostaglandin F2alpha synthesis, ovary leads to Reduced, Prostaglandin F2alpha concentration, plasma
672 Reduced, Prostaglandin F2alpha concentration, plasma leads to Reduced, Spawning behavior
673 Reduced, Spawning behavior leads to Reduced, Ability to attract spawning mates
674 Reduced, Ability to attract spawning mates leads to Reduced, Reproductive Success
675 Reduced, Reproductive Success leads to Decrease, Population trajectory
678 Reduced, Prostaglandin F2alpha concentration, plasma leads to Reduced, Pheromone release
679 Reduced, Pheromone release leads to Reduced, Ability to attract spawning mates
681 Inhibition, Cyclooxygenase activity leads to Decreased, Prostaglandin F2alpha synthesis, ovary
682 Decreased, Prostaglandin F2alpha synthesis, ovary leads to Reduced, Prostaglandin F2alpha concentration, plasma
683 Reduction, Neuronal synaptic inhibition leads to Generation, Amplified excitatory postsynaptic potential (EPSP)
684 Generation, Amplified excitatory postsynaptic potential (EPSP) leads to Occurrence, A paroxysmal depolarizing shift
685 Reduced, Prostaglandins, ovary leads to Decrease, Ovulation
686 Inhibition, Cyclooxygenase activity leads to Reduced, Prostaglandins, ovary
687 Decrease, Ovulation leads to Reduced, Reproductive Success
689 Inhibition, Cyclooxygenase activity leads to Reduced, Prostaglandin E2 concentration, hypothalamus
690 Reduced, Prostaglandin E2 concentration, hypothalamus leads to Reduced, Gonadotropin releasing hormone, hypothalamus
691 Reduced, Gonadotropin releasing hormone, hypothalamus leads to Reduced, Luteinizing hormone (LH), plasma
692 Reduced, Luteinizing hormone (LH), plasma leads to Reduced, Maturation inducing steroid, plasma
693 Reduced, Maturation inducing steroid, plasma leads to Reduced, Maturation inducing steroid receptor signalling, oocyte
694 Reduced, Maturation inducing steroid receptor signalling, oocyte leads to Increased, cyclic adenosine monophosphate
695 Increased, cyclic adenosine monophosphate leads to Reduced, Reproductive Success
696 Increased, cyclic adenosine monophosphate leads to Reduced, Meiotic prophase I/metaphase I transition, oocyte
697 Reduced, Meiotic prophase I/metaphase I transition, oocyte leads to Reduced, Reproductive Success
698 Reduced, Maturation inducing steroid receptor signalling, oocyte leads to Upregulated, Spindle assembly checkpoint protein Mad2-oocyte
699 Upregulated, Spindle assembly checkpoint protein Mad2-oocyte leads to Increased, Chromosome misseggregation
700 Increased, Chromosome misseggregation leads to Reduced, Reproductive Success
701 impaired, ion channels leads to Altered, Action Potential
702 Altered, Action Potential leads to Increased, cardiac arrthymia
703 Increased, cardiac arrthymia leads to Increased Mortality
706 Increased, Binding of chemicals to 2u (serum) leads to Increased, Accumulation of alpha2u microglobulin (proximal tubular epithelium)
707 Increased, Accumulation of alpha2u microglobulin (proximal tubular epithelium) leads to Increase, Cytotoxicity (renal tubular cell)
708 Increase, Cytotoxicity (renal tubular cell) leads to Increase, Regenerative cell proliferation (tubular epithelial cells)
711 Activation, Constitutive androstane receptor leads to Increase, Mitogenic cell proliferation (hepatocytes)
714 Binding, Tubulin leads to Disruption, Microtubule dynamics
715 Disruption, Microtubule dynamics leads to Disorganization, Spindle
716 Inhibition, Pyruvate dehydrogenase kinase (PDK) enzyme leads to Increased, Induction of pyruvate dehydrogenase (PDH)
723 Altered, Chromosome number leads to Increase, Aneuploid offspring
724 Binding, Tubulin leads to Altered, Chromosome number
726 Increase, Necrosis (terminal bronchiolar cells) leads to Increase, Regenerative cell proliferation (terminal bronchiolar epithelial cells)
727 Increase, Regenerative cell proliferation (terminal bronchiolar epithelial cells) leads to Increase, Hyperplasia (terminal bronchiolar cells)
728 Increase, Hyperplasia (terminal bronchiolar cells) leads to Increase, Adenomas/carcinomas (bronchioloalveolar)
729 Decreased, Androgen receptor activity leads to Decreased, Testosterone binding to androgen receptor (hypothalamus)
730 Decreased, Testosterone binding to androgen receptor (hypothalamus) leads to Increase, Hyperplasia (Leydig cells)
731 Increase, Hyperplasia (Leydig cells) leads to Increase, Leydig cell tumors
732 Increase, Dopaminergic activity leads to Decreased, Prolactin
733 Decreased, Prolactin leads to Increased, Estrogen receptor (ER) activity
734 Increased, Estrogen receptor (ER) activity leads to Decreased, Progesterone from corpus luteum
737 Disorganization, Spindle leads to Altered, Meiotic chromosome dynamics
738 Altered, Meiotic chromosome dynamics leads to Altered, Chromosome number
741 Increase, Thyroid-stimulating hormone (TSH) leads to Increase, Hypertrophy and proliferation (follicular cell)
742 Increase, Hypertrophy and proliferation (follicular cell) leads to Increase, Hyperplasia (follicular cells)
743 Increase, Hyperplasia (follicular cells) leads to Increase, Adenomas/carcinomas (follicular cell)
744 Decreased, Testosterone binding to androgen receptor (hypothalamus) leads to Increased, Luteinizing hormone (LH)
745 Increased, Luteinizing hormone (LH) leads to Increase, Hyperplasia (Leydig cells)
746 T4 in neuronal tissue, Decreased leads to Hippocampal gene expression, Altered
747 Hippocampal gene expression, Altered leads to Hippocampal anatomy, Altered
748 Hippocampal Physiology, Altered leads to Cognitive Function, Decreased
749 Hippocampal anatomy, Altered leads to Hippocampal Physiology, Altered
750 Activation, 5HT2c leads to N/A, Unknown
751 N/A, Unknown leads to Increased, Kidney Failure
752 Activation, Glutamate-gated chloride channel leads to Increased, Chloride conductance
755 hyperpolarisation, neuron leads to N/A, Ataxia, paralysis, or hyperactivity
756 Increased Mortality leads to Decreased, population 1
757 N/A, Ataxia, paralysis, or hyperactivity leads to Increased Mortality
758 Increased, Chloride conductance leads to hyperpolarisation, neuron
759 Neuroinflammation leads to Synaptogenesis, Decreased
760 Increase, Regenerative cell proliferation (tubular epithelial cells) leads to Increase, Hyperplasia (renal tubular cells)
761 Increase, Hyperplasia (renal tubular cells) leads to Increase, Adenomas/carcinomas (renal tubular)
762 Increased, Induction of pyruvate dehydrogenase (PDH) leads to Increase, Oxidative metabolism
763 Increase, Oxidative metabolism leads to Peptide Oxidation
764 Peptide Oxidation leads to Increase, Adenomas/carcinomas (hepatocellular)
765 Peptide Oxidation leads to Increase, Cytotoxicity
766 Increase, Cytotoxicity leads to Increase, Adenomas/carcinomas (hepatocellular)
767 Increase, Cytotoxicity (club cells) leads to Increase, Necrosis (terminal bronchiolar cells)
768 Decreased, Uptake of inorganic iodide leads to Decrease, Serum thyroid hormone (T4/T3)
769 Decrease, Serum thyroid hormone (T4/T3) leads to Increase, Thyroid-stimulating hormone (TSH)
770 Increase, Dopaminergic activity leads to Increase, Endometrial adenocarcinomas
771 Increase, Hyperplasia (glandular epithelial cells of endometrium) leads to Increase, Endometrial adenocarcinomas
772 Decreased, Progesterone from corpus luteum leads to Increase, Hyperplasia (glandular epithelial cells of endometrium)
773 Increase, Mitogenic cell proliferation (hepatocytes) leads to Increase, Preneoplastic foci (hepatocytes)
774 Increase, Preneoplastic foci (hepatocytes) leads to Increase, Adenomas/carcinomas (hepatocellular)
775 Inhibition, 4-hydroxyphenyl-pyruvate dioxygenase (HPPD) enzyme leads to Increased, Plasma tyrosine
776 Increased, Plasma tyrosine leads to Increase, Cytotoxicity (corneal cells)
777 Increase, Cytotoxicity (corneal cells) leads to Increase, Inflammation (corneal cells)
778 Increase, Inflammation (corneal cells) leads to Increase, Regenerative cell proliferation (corneal cells)
779 Increase, Regenerative cell proliferation (corneal cells) leads to Increase, Papillomas/carcinomas (squamous cells)
780 Increase, Cytotoxicity (epithelial cells) leads to Increase, Inflammation
781 Increase, Inflammation leads to Increase, Regenerative cell proliferation (forestomach epithelial cells)
782 Increase, Regenerative cell proliferation (forestomach epithelial cells) leads to Increase, Hyperplasia (forestomach epithelial cells)
783 Increase, Hyperplasia (forestomach epithelial cells) leads to Increase, Papillomas/carcinomas (squamous cells)
784 Increase, Cytotoxicity (tubular epithelial cells) leads to Increase, Regenerative cell proliferation (tubular epithelial cells)
785 Increase, Regenerative cell proliferation (tubular epithelial cells) leads to Increase, Hyperplasia (tubular epithelial cells)
786 Increase, Hyperplasia (tubular epithelial cells) leads to Increase, Adenomas/carcinomas (renal tubular)
787 Activation, Androgen receptor leads to Increase, Mitogenic cell proliferation (hepatocytes)
788 Increase, Cytotoxicity (hepatocytes) leads to Increase, Regenerative cell proliferation (hepatocytes)
789 Increase, Regenerative cell proliferation (hepatocytes) leads to Increase, Preneoplastic foci (hepatocytes)
790 Thyroperoxidase, Inhibition leads to Decrease, Incorporation of active iodide into iodotyrosines
791 Decrease, Incorporation of active iodide into iodotyrosines leads to Decrease, Serum thyroid hormone (T4/T3)
792 Inhibition, 5α-reductase activity leads to Decrease, Bioactivation of testosterone
793 Decrease, Bioactivation of testosterone leads to Increased, Leutinizing hormone (LH)
794 Increased, Leutinizing hormone (LH) leads to Increase, Hyperplasia (Leydig cells)
795 Increase, Urinary bladder calculi leads to Increase, Cytotoxicity (urothelial cells)
796 Increase, Cytotoxicity (urothelial cells) leads to Increase, Regenerative cell proliferation (urothelial cells)
797 Increase, Regenerative cell proliferation (urothelial cells) leads to Increase, Hyperplasia (urothelial)
798 Increase, Hyperplasia (urothelial) leads to Increase, Adenomas/carcinomas (urothelial)
799 Inhibition, Prolyl hydroxylases leads to Increased, HIF-1 heterodimer
800 Increased, HIF-1 heterodimer leads to Decreased, Aromatase (Cyp19a1) mRNA
801 Decreased, Aromatase (Cyp19a1) mRNA leads to Reduction, 17beta-estradiol synthesis by ovarian granulosa cells
802 modulation, Unknown leads to Increased, HIF-1 alpha transcription
803 Increased, HIF-1 alpha transcription leads to Increased, HIF-1 heterodimer
804 Inhibition, HMG-CoA reductase leads to Decreased, mevalonate
805 Decreased, mevalonate leads to Decreased, cholesterol
806 Decreased, cholesterol leads to Decreased, Testosterone
807 Decreased, Testosterone leads to malformed, Male reproductive tract
808 malformed, Male reproductive tract leads to Decrease, Fertility
809 TH synthesis, Decreased leads to Decreased, Thyroxine (T4) in serum
810 TH synthesis, Decreased leads to Increased, Serum creatinine
811 Decreased, Thyroxine (T4) in serum leads to Occurrence, Cytoplasmic vacuolization (Renal tubule)
812 Decreased, Thyroxine (T4) in serum leads to Occurrence, Cystic dilatation (renal tubule)
813 Increased, Serum creatinine leads to Occurrence, Cytoplasmic vacuolization (Renal tubule)
814 Increased, Serum creatinine leads to Occurrence, Cystic dilatation (renal tubule)
815 Decreased, Thyroxine (T4) in serum leads to Occurrence, Cytoplasmic vacuolization (podocyte)
816 Increased, Serum creatinine leads to Occurrence, Cytoplasmic vacuolization (podocyte)
817 Occurrence, Cytoplasmic vacuolization (Renal tubule) leads to Decreased, Glomerular filtration
818 Occurrence, Cytoplasmic vacuolization (Renal tubule) leads to Decreased, Renal plasma flow
819 Occurrence, Cytoplasmic vacuolization (Renal tubule) leads to Decreased, Sodium reabsorption
820 Occurrence, Cytoplasmic vacuolization (Renal tubule) leads to Decreased, Renal ability to dilute urine
821 Occurrence, Cystic dilatation (renal tubule) leads to Decreased, Glomerular filtration
822 Occurrence, Cystic dilatation (renal tubule) leads to Decreased, Renal plasma flow
823 Occurrence, Cystic dilatation (renal tubule) leads to Decreased, Sodium reabsorption
824 Occurrence, Cystic dilatation (renal tubule) leads to Decreased, Renal ability to dilute urine
825 Occurrence, Cytoplasmic vacuolization (podocyte) leads to Decreased, Glomerular filtration
826 Occurrence, Cytoplasmic vacuolization (podocyte) leads to Decreased, Renal plasma flow
827 Occurrence, Cytoplasmic vacuolization (podocyte) leads to Decreased, Sodium reabsorption
828 Occurrence, Cytoplasmic vacuolization (podocyte) leads to Decreased, Renal ability to dilute urine
829 Decreased, Glomerular filtration leads to Occurrence, Kidney toxicity
830 Decreased, Renal plasma flow leads to Occurrence, Kidney toxicity
831 Decreased, Sodium reabsorption leads to Occurrence, Kidney toxicity
832 Decreased, Renal ability to dilute urine leads to Occurrence, Kidney toxicity
833 Covalent Binding, Protein leads to Activation, Keratinocytes
834 Activation, Keratinocytes leads to Activation, Dendritic Cells
835 Activation/Proliferation, T-cells leads to sensitisation, skin
836 Inhibition, Phospholipase A leads to Damage, Lipid bilayer
837 Inhibition, Phospholipase A leads to Disturbance, Lysosomal function
838 Inhibition, Phospholipase A leads to Injury, Mitochondria
839 Damage, Lipid bilayer leads to Occurrence, Cytoplasmic vacuolization (hepatocyte)
840 Damage, Lipid bilayer leads to Occurrence, Ballooning degeneration (hepatocyte)
841 Damage, Lipid bilayer leads to Occurrence, Cytoplasmic vacuolization (Bile duct cell)
842 Damage, Lipid bilayer leads to Occurrence, Cytoplasmic vacuolization (kupffer cell)
843 Disturbance, Lysosomal function leads to Occurrence, Cytoplasmic vacuolization (hepatocyte)
844 Disturbance, Lysosomal function leads to Occurrence, Ballooning degeneration (hepatocyte)
845 Disturbance, Lysosomal function leads to Occurrence, Cytoplasmic vacuolization (Bile duct cell)
846 Disturbance, Lysosomal function leads to Occurrence, Cytoplasmic vacuolization (kupffer cell)
847 Injury, Mitochondria leads to Occurrence, Cytoplasmic vacuolization (hepatocyte)
848 Injury, Mitochondria leads to Occurrence, Ballooning degeneration (hepatocyte)
849 Injury, Mitochondria leads to Occurrence, Cytoplasmic vacuolization (Bile duct cell)
850 Injury, Mitochondria leads to Occurrence, Cytoplasmic vacuolization (kupffer cell)
851 Occurrence, Cytoplasmic vacuolization (hepatocyte) leads to Induction, Microvesicular fat
852 Occurrence, Cytoplasmic vacuolization (hepatocyte) leads to Formation, Mallory body
853 Occurrence, Ballooning degeneration (hepatocyte) leads to Induction, Microvesicular fat
854 Occurrence, Ballooning degeneration (hepatocyte) leads to Formation, Mallory body
855 Occurrence, Cytoplasmic vacuolization (Bile duct cell) leads to Induction, Microvesicular fat
856 Occurrence, Cytoplasmic vacuolization (Bile duct cell) leads to Formation, Mallory body
857 Occurrence, Cytoplasmic vacuolization (kupffer cell) leads to Induction, Microvesicular fat
858 Occurrence, Cytoplasmic vacuolization (kupffer cell) leads to Formation, Mallory body
859 Induction, Microvesicular fat leads to Formation, Liver fibrosis
860 Formation, Mallory body leads to Formation, Liver fibrosis
864 Oxidation, Uroporphyrinogen leads to Accumulation, Highly carboxylated porphyrins
865 Oxidation, Uroporphyrinogen leads to Inhibition, UROD
866 Accumulation, Highly carboxylated porphyrins leads to Uroporphyria
867 Inhibition, UROD leads to Oxidation, Uroporphyrinogen
868 Induction, CYP1A2/CYP1A5 leads to Oxidation, Uroporphyrinogen
869 Activation, AhR leads to Induction, CYP1A2/CYP1A5
870 BDNF, Reduced leads to GABAergic interneurons, Decreased
871 GABAergic interneurons, Decreased leads to Synaptogenesis, Decreased
872 Thyroidal Iodide, Decreased leads to TH synthesis, Decreased
874 Activation, Long term AHR receptor driven direct and indirect gene expression changes leads to Changes/Inhibition, Cellular Homeostasis and Apoptosis
875 Activation, Long term AHR receptor driven direct and indirect gene expression changes leads to Alterations, Cellular proliferation / hyperplasia
876 Activation, Long term AHR receptor driven direct and indirect gene expression changes leads to Formation, Hepatocellular and Bile duct tumors
877 Binding as antagonist, Antagonist binding to PPARalpha ligand binding domain leads to Decreased, PPARalpha transactivation of gene expression
878 Decreased, PPARalpha transactivation of gene expression leads to Decreased, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids
879 Decreased, PPARalpha transactivation of gene expression leads to Decreased, Mitochondrial Fatty Acid Beta Oxidation
880 Decreased, PPARalpha transactivation of gene expression leads to Decreased, Ketogenesis (production of ketone bodies)
881 Decreased, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids leads to Decreased, Mitochondrial Fatty Acid Beta Oxidation
882 Decreased, Mitochondrial Fatty Acid Beta Oxidation leads to Decreased, Ketogenesis (production of ketone bodies)
883 Decreased, Ketogenesis (production of ketone bodies) leads to Not Increased, Circulating Ketone Bodies
884 Not Increased, Circulating Ketone Bodies leads to Increased, Catabolism of Muscle Protein
885 Increased, Catabolism of Muscle Protein leads to Decreased, Body Weight
886 Decrease, Intracellular pH leads to Increase, Cytotoxicity
887 Increase, Cytotoxicity leads to Increase, Tissue Degeneration, Necrosis & Atrophy
888 Increase, Tissue Degeneration, Necrosis & Atrophy leads to Increase, Respiratory or Squamous Metaplasia
889 Increase, Respiratory or Squamous Metaplasia leads to Increase, Cell Proliferation
890 Increase, Cell Proliferation leads to Increased, Induced Mutations in Critical Genes
891 Increased, Induced Mutations in Critical Genes leads to Increase, Site of Contact Nasal Tumors
892 Increased, Intracellular Calcium overload leads to Decreased, Neuronal network function in adult brain
893 Increase, Cell Proliferation leads to Increase, Mutations in Critical Genes
894 Increase, Mutations in Critical Genes leads to Increase, Site of Contact Nasal Tumors
895 Increase, Cell Proliferation leads to Increase, Site of Contact Nasal Tumors
896 Activation, SHP leads to Inhibition, SREBP1c
899 Increase, Mutations leads to Increase, Cancer
901 Alkylation, DNA leads to Increase, Cancer
904 N/A, Mitochondrial dysfunction 1 leads to Impaired, Proteostasis
905 Impaired, Proteostasis leads to Degeneration of dopaminergic neurons of the nigrostriatal pathway
906 Neuroinflammation leads to Degeneration of dopaminergic neurons of the nigrostriatal pathway
907 Degeneration of dopaminergic neurons of the nigrostriatal pathway leads to Neuroinflammation
908 N/A, Mitochondrial dysfunction 1 leads to Degeneration of dopaminergic neurons of the nigrostriatal pathway
910 Degeneration of dopaminergic neurons of the nigrostriatal pathway leads to Parkinsonian motor deficits
911 Disruption, Lysosome leads to Increase, ROS production
912 Increase, ROS production leads to N/A, Mitochondrial dysfunction 1
916 Infiltration, Inflammatory cells leads to Inflammation, Liver
919 Binding of agonist, Ionotropic glutamate receptors leads to Overactivation, NMDARs
921 Disruption, Lysosome leads to Peptide Oxidation
922 Peptide Oxidation leads to N/A, Mitochondrial dysfunction 1
923 Peptide Oxidation leads to Release, Cytokine
924 Cell injury/death leads to Release, Cytokine
925 Release, Cytokine leads to Infiltration, Inflammatory cytokines
926 Infiltration, Inflammatory cytokines leads to Inflammation, Liver
927 Inhibition, Bile Salt Export Pump (ABCB11) leads to Bile accumulation, Pathological condition
928 Bile accumulation, Pathological condition leads to Release, Cytokine
929 Increase, Inflammation leads to Cholestasis, Pathology
930 Bile accumulation, Pathological condition leads to Production, Reactive oxygen species
931 Production, Reactive oxygen species leads to Cholestasis, Pathology
932 Peptide Oxidation leads to Cholestasis, Pathology
933 Binding of inhibitor, NADH-ubiquinone oxidoreductase (complex I) leads to Inhibition, NADH-ubiquinone oxidoreductase (complex I)
934 Inhibition, NADH-ubiquinone oxidoreductase (complex I) leads to N/A, Mitochondrial dysfunction 1
936 Activation, Epidermal Growth Factor Receptor leads to Decrease, Apoptosis of ciliated epithelial cells
939 Activation, Epidermal Growth Factor Receptor leads to Increase, Proliferation of goblet cells
942 Activation, Epidermal Growth Factor Receptor leads to Occurrence, Transdifferentiation of ciliated epithelial cells
943 Occurrence, Transdifferentiation of ciliated epithelial cells leads to Occurrence, Metaplasia of goblet cells
944 Increase, Proliferation of goblet cells leads to Goblet cell hyperplasia
946 Activation, Epidermal Growth Factor Receptor leads to Activation, Sp1
948 Peptide Oxidation leads to Oxidation, Glutathione
952 Decrease, GTPCH-1 leads to Decrease, Tetrahydrobiopterin
953 Decrease, Tetrahydrobiopterin leads to Uncoupling, eNOS
954 Oxidation, Glutathione leads to S-Glutathionylation, eNOS
955 S-Glutathionylation, eNOS leads to Uncoupling, eNOS
956 Uncoupling, eNOS leads to Depletion, Nitric Oxide
958 Depletion, Nitric Oxide leads to Impaired, Vasodilation
961 Decrease, Apoptosis of ciliated epithelial cells leads to Occurrence, Transdifferentiation of ciliated epithelial cells
962 Activation, EGFR leads to Decrease, Apoptosis of ciliated epithelial cells
964 Activation, EGFR leads to Activation, Sp1
965 Activation, EGFR leads to Occurrence, Transdifferentiation of ciliated epithelial cells
970 Activation, EGFR leads to Increase, Proliferation of goblet cells
972 Activation, AhR leads to dimerization, AHR/ARNT
973 dimerization, AHR/ARNT leads to reduced dimerization, ARNT/HIF1-alpha
974 reduced dimerization, ARNT/HIF1-alpha leads to reduced production, VEGF
975 reduced production, VEGF leads to Impairment, Endothelial network
976 Impairment, Endothelial network leads to Altered, Cardiovascular development/function
977 Altered, Cardiovascular development/function leads to Increase, Pericardial edema
980 Peptide Oxidation leads to Decrease, GTPCH-1
982 Impaired, Vasodilation leads to Increase, Vascular Resistance
983 Increase, Vascular Resistance leads to Hypertension
984 Activation, AhR leads to Increase, Early Life Stage Mortality
986 Activation, EGFR leads to Increase, Mucin production
987 Activation, Sp1 leads to Increase, Mucin production
988 Decrease, AKT/eNOS activity leads to Depletion, Nitric Oxide
989 Goblet cell hyperplasia leads to Hypersecretion, Mucus
990 Occurrence, Metaplasia of goblet cells leads to Hypersecretion, Mucus
991 Increase, Mucin production leads to Hypersecretion, Mucus
992 Peptide Oxidation leads to Decrease, AKT/eNOS activity
993 Disruption, Lysosome leads to N/A, Mitochondrial dysfunction 1
994 Release, Cytokine leads to Infiltration, Inflammatory cells
995 Changes/Inhibition, Cellular Homeostasis and Apoptosis leads to N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects
996 N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects leads to Alterations, Cellular proliferation / hyperplasia
997 Alterations, Cellular proliferation / hyperplasia leads to Formation, Hepatocellular and Bile duct tumors
998 Increase, EcR agonism leads to Decrease, Circulating ETH
999 Increase, EcR agonism leads to Decreased, synthesis and secretion of molting fluid proteases
1000 Decrease, Circulating ETH leads to Increase, Incomplete ecdysis
1001 Decreased, synthesis and secretion of molting fluid proteases leads to Increase, Incomplete ecdysis
1002 Increase, Incomplete ecdysis leads to Increase, Mortality
1004 Increase, Mortality leads to Decreased, population 1
1007 Increase, EcR agonism leads to Decreased, Synthesis of molting fluid proteases
1008 Decrease, Circulating ETH leads to Decrease, Abdominal muscle contraction
1009 Decreased, Synthesis of molting fluid proteases leads to Decrease, Digestion of old cuticle
1010 Decrease, Abdominal muscle contraction leads to Increase, Incomplete ecdysis
1011 Decrease, Digestion of old cuticle leads to Increase, Incomplete ecdysis
1013 Increase, Mortality leads to Decreased, Population size
1015 Inhibition, Calcineurin Activity leads to Activation, Suppression of NFAT activation and hindrance of nuclear localization
1016 Activation, Suppression of NFAT activation and hindrance of nuclear localization leads to Interference, nuclear localization of NFAT
1017 Interference, nuclear localization of NFAT leads to Reduction, NFAT/AP-1 complex formation
1018 Reduction, NFAT/AP-1 complex formation leads to Suppression, Suppression in mixed lymphocyte reaction (MLR)
1019 Reduction, NFAT/AP-1 complex formation leads to Suppression, Suppression of T-cell dependent antibody response (TDAR)
1020 Reduction, NFAT/AP-1 complex formation leads to Impairment, T-cell dependent antibody response
1021 Reduction, NFAT/AP-1 complex formation leads to Relief, Relief of atopic dermatitis
1022 Reduction, NFAT/AP-1 complex formation leads to Increase, Increased susceptibility to infection
1023 Binding of antagonist, PPAR alpha leads to stabilization, PPAR alpha co-repressor
1024 stabilization, PPAR alpha co-repressor leads to Decreased, PPARalpha transactivation of gene expression
1025 Abnormal, Morphogenesis leads to Increased, Developmental Defects
1026 Inhibition, Deiodinase 2 leads to Decreased, Triiodothyronine (T3) in serum
1027 Decreased, Triiodothyronine (T3) in serum leads to Reduced, Posterior swim bladder inflation
1028 Reduced, Posterior swim bladder inflation leads to Reduced, Swimming performance
1029 Reduced, Swimming performance leads to Reduced, Young of year survival
1030 Reduced, Young of year survival leads to Decrease, Population trajectory
1031 Reduced, Posterior swim bladder inflation leads to Reduced, Anterior swim bladder inflation
1032 Reduced, Anterior swim bladder inflation leads to Reduced, Hearing
1033 Reduced, Hearing leads to Reduced, Young of year survival
1034 Reduced, Anterior swim bladder inflation leads to Reduced, Swimming performance
1035 Decreased, Triiodothyronine (T3) in serum leads to Reduced, Anterior swim bladder inflation
1036 Insufficiency, Vascular leads to Increased, Developmental Defects
1037 Inhibition, Deiodinase 1 leads to Decreased, Triiodothyronine (T3) in serum
1039 T4 in serum, Decreased leads to Reduced, Anterior swim bladder inflation
1040 Thyroperoxidase, Inhibition leads to Reduced, Anterior swim bladder inflation
1041 Reduced, Posterior swim bladder inflation leads to Reduced, Young of year survival
1042 Inhibition, Deiodinase 2 leads to Reduced, Posterior swim bladder inflation
1043 Inhibition, Deiodinase 2 leads to Reduced, Anterior swim bladder inflation
1044 Inhibition, Deiodinase 1 leads to Reduced, Posterior swim bladder inflation
1045 Inhibition, Deiodinase 1 leads to Reduced, Anterior swim bladder inflation
1047 Increased, Chloride influx leads to Increased, Inhibitory postsynaptic potential
1048 Increased, Inhibitory postsynaptic potential leads to Inhibition, Motor neuron activity
1049 Inhibition, Motor neuron activity leads to Induction, Somatic muscle paralysis
1050 Induction, Somatic muscle paralysis leads to Increased Mortality
1051 Activation, ionotropic GABA Receptor chloride channel leads to Increased, Chloride conductance
1052 Increased, Chloride conductance leads to Increased, Neuronal synaptic inhibition
1053 Increased, Neuronal synaptic inhibition leads to Increased, Inhibitory postsynaptic potential
1054 Increased, Inhibitory postsynaptic potential leads to Induction, Somatic muscle paralysis
1055 Induction, Somatic muscle paralysis leads to Inhibition, Feeding
1056 Inhibition, Feeding leads to Increased Mortality
1057 Activation, Glutamate-gated chloride channels leads to Increased, Chloride conductance
1058 Increased, Inhibitory postsynaptic potential leads to Induction, pharyngeal muscle paralysis
1059 Induction, pharyngeal muscle paralysis leads to Inhibition, Feeding
1061 Antagonism, Histamine Receptor (H2) leads to Decrease, histaminergic neuron excitation
1062 Formation, The binding of FK506 with FKBP12 leads to Inhibition, Calcineurin Activity
1063 Increased, induction of UDPGT's in liver leads to Increased, T4/T3 catabolism
1064 Increased, T4/T3 catabolism leads to Decreased, serum T4/T3
1065 Decreased, serum T4/T3 leads to Increased, Thyroid-stimulating hormone (TSH)
1066 Increased, Thyroid-stimulating hormone (TSH) leads to Increased, Hypertrophy and proliferation (follicular cell)
1067 Increased, Hypertrophy and proliferation (follicular cell) leads to Increased, Hyperplasia (follicular cells)
1068 Increased, Hyperplasia (follicular cells) leads to Increased Apoptosis, Adenomas/carcinomas (follicular cell)
1069 N/A, Neurodegeneration leads to Impairment, Learning and memory
1070 Inhibition, UROD leads to Accumulation, Highly carboxylated porphyrins
1071 Activation of specific nuclear receptors, PPAR-gamma activation leads to Increased, adipogenesis
1072 Activation of specific nuclear receptors, PPAR-gamma activation leads to Increased, secretion of local growth factors
1073 Increased, adipogenesis leads to Increased, secretion of local growth factors
1074 Increased, secretion of local growth factors leads to Increased, proliferation of mesenchymal cells
1075 Increased, secretion of local growth factors leads to Increased, IGF-1 (mouse)
1076 Increased, proliferation of mesenchymal cells leads to Increased, Firbrosarcoma
1077 Increased, proliferation of mesenchymal cells leads to Increased, liposarcoma
1078 Increased, proliferation of mesenchymal cells leads to Increased, hemagiosarcoma
1079 Activation, beta-2 adrenergic receptor leads to Increased activity, beta-2 adrenergic receptor
1080 Increased activity, beta-2 adrenergic receptor leads to relaxation, smooth muscle
1081 relaxation, smooth muscle leads to Proliferation/Clonal Expansion, smooth muscle
1082 Proliferation/Clonal Expansion, smooth muscle leads to Hypertrophy/hyperplasia, smooth muscle
1083 Hypertrophy/hyperplasia, smooth muscle leads to Promotion, mesovarian leiomyomas
1084 Decreased, Ovarian E2 leads to Increased, secretion of GnRH from hypothalamus
1085 Decreased, Ovarian E2 leads to Decrease, E2 blood concentrations at hypothalamus
1086 Suppression, Estrogen receptor (ER) activity leads to Decrease, E2 blood concentrations at hypothalamus
1087 Decrease, E2 blood concentrations at hypothalamus leads to Increased, secretion of GnRH from hypothalamus
1088 Increased, secretion of GnRH from hypothalamus leads to Increased, secrection of FSH from anterior pituitary
1089 Increased, secretion of GnRH from hypothalamus leads to Increased, secretion of LH from anterior pituitary
1090 Increased, secrection of FSH from anterior pituitary leads to Hyperplasia, ovarian stromal cells
1091 Increased, secrection of FSH from anterior pituitary leads to Hyperplasia, ovarian epithelium
1092 Increased, secretion of LH from anterior pituitary leads to Hyperplasia, ovarian stromal cells
1093 Hyperplasia, ovarian epithelium leads to Promotion, ovarian adenomas
1094 Hyperplasia, ovarian stromal cells leads to Promotion, ovarian granular cell tumors
1095 Increased, PPAR-alpha activation leads to Decreased, bile flow
1096 Increased, PPAR-alpha activation leads to Increased, cholestasis
1097 Increased, PPAR-alpha activation leads to Alteration, lipid metabolism
1098 prolonged, elevation of serun CCK leads to Increased, Cellular proliferation / hyperplasia of acinar cells
1099 Increased, Cellular proliferation / hyperplasia of acinar cells leads to Increased, Pancreatic acinar tumors
1100 Increased, cholestasis leads to prolonged, elevation of serun CCK
1101 Decreased, bile flow leads to Increased, cholestasis
1102 prepubertal increase, Estrogen receptor (ER) activity leads to Activation, estrogen receptor alpha
1103 Activation, estrogen receptor alpha leads to Promotion, SIX-1 postive basal-type progenitor cells
1104 Promotion, SIX-1 postive basal-type progenitor cells leads to Proliferation/Clonal Expansion, aberrant basal cells
1105 Proliferation/Clonal Expansion, aberrant basal cells leads to squamous metaplasia, aberrant basal cells
1106 squamous metaplasia, aberrant basal cells leads to Increased, Hyperplasia (glandular epithelial cells of endometrium)
1107 Increased, Hyperplasia (glandular epithelial cells of endometrium) leads to Increased, adenosquamous carcinomas of endometrium
1108 Decreased, GnRH pulsatility/release in hypothalamus leads to Decreased, LH Surge from anterior pituitary
1109 Decreased, LH Surge from anterior pituitary leads to interruption, Ovulation
1110 Decreased, LH Surge from anterior pituitary leads to prolonged, estrus
1111 prolonged, estrus leads to Increased, circulating estrogen levels
1112 prolonged, estrus leads to Increased, prolactin exposure
1113 Increased, circulating estrogen levels leads to Hyperplasia, Mammary gland
1114 Increased, prolactin exposure leads to Hyperplasia, Mammary gland
1115 Hyperplasia, Mammary gland leads to Increased, latency period
1116 Hyperplasia, Mammary gland leads to Increased, Adenomas/carcinomas (mammary)
1117 Increased, latency period leads to Increased, Adenomas/carcinomas (mammary)
1118 interruption, Ovulation leads to Increased, circulating estrogen levels
1119 Increased, circulating estrogen levels leads to Increased, lactotroph hyperplasia and hypertrophy
1120 Increased, lactotroph hyperplasia and hypertrophy leads to Increased, adenomas (pituitary)
1121 Decreased, Dopaminergic activity leads to Increased, prolactin secretion
1122 Increased, prolactin secretion leads to Increased, hyperplasia (mammary gland)
1123 Increased, hyperplasia (mammary gland) leads to Increased, latency period
1124 Increased, hyperplasia (mammary gland) leads to Increased, Adenomas/carcinomas (mammary)
1125 persistent, cytotoxicity (pleura or peritoneum) leads to Increased, inflammation
1126 persistent, cytotoxicity (pleura or peritoneum) leads to Increased, Oxidative Stress
1127 Increased, inflammation leads to Increased, secretion of local growth factors
1128 Increased, Oxidative Stress leads to Increased, secretion of local growth factors
1129 Increased, secretion of local growth factors leads to Increased, Cell Proliferation (mesothelium)
1130 Increased, Cell Proliferation (mesothelium) leads to Increased, mesotheliomas
1131 Inhibition, organic anion transporter 1 (OAT1) leads to Increased, blood uric acid concentration
1132 Increased, blood uric acid concentration leads to Occurrence, tophi (urate) deposition
1133 Occurrence, tophi (urate) deposition leads to Occurrence, renal proximal tubular necrosis
1134 Occurrence, renal proximal tubular necrosis leads to Increased, blood potassium concentration
1135 Increased, blood potassium concentration leads to Occurrence, cardiac arrthymia
1136 Occurrence, cardiac arrthymia leads to Increased Mortality
1137 Inhibition, Cyclooxygenase 1 activity leads to Decreased, Prostaglandin F2alpha concentration, plasma
1138 Decreased, Prostaglandin F2alpha concentration, plasma leads to Occurrence, renal ischemia
1139 Occurrence, renal ischemia leads to Occurrence, renal proximal tubular necrosis
1140 Increased, blood potassium concentration leads to Occurrence, cardiac arrhythmia
1141 Occurrence, cardiac arrhythmia leads to Increased Mortality
1142 Decreased, Thyroxine (T4) in tissues leads to Altered, Amphibian metamorphosis
1143 T4 in serum, Decreased leads to Decreased, Thyroxine (T4) in tissues
1144 Abnormal, Foraging activity and behavior leads to Weakened, Colony
1145 Weakened, Colony leads to Death/Failure, Colony
1146 Activation, Nicotinic acetylcholine receptor leads to Impairment, Learning and memory
1147 Activation, Nicotinic acetylcholine receptor leads to Abnormal, Foraging activity and behavior
1148 Abnormal, Foraging activity and behavior leads to Abnormal, Roll change within caste
1149 Abnormal, Roll change within caste leads to Weakened, Colony
1150 Abnormal, Foraging activity and behavior leads to Abnormal, Role change within caste
1151 Abnormal, Role change within caste leads to Weakened, Colony
1152 N/A, Mitochondrial dysfunction 1 leads to impaired, Hive thermoregulation
1153 impaired, Hive thermoregulation leads to Weakened, Colony
1154 N/A, Mitochondrial dysfunction 1 leads to Weakened, Colony
1155 Increased, Deformed Wing Virus levels leads to Weakened, Colony
1156 Occurrence, renal proximal tubular necrosis leads to Increased, blood uric acid concentration
1157 Increased, Energetic demands and therefore metabolic stress leads to Abnormal, Foraging activity and behavior
1158 Increased, blood uric acid concentration leads to Increased, Oxidative Stress
1159 Occurrence, renal ischemia leads to Increased, Oxidative Stress
1160 Increased, Oxidative Stress leads to Occurrence, renal proximal tubular necrosis
1161 Unknown, MIE leads to Increased, Reactive oxygen species
1162 Increased, Reactive oxygen species leads to Increased, Oxidative Stress
1163 Decreased, Thyroxine (T4) in tissues leads to Decreased, Triiodothyronine (T3) in tissues
1164 Decreased, Triiodothyronine (T3) in tissues leads to Altered, Amphibian metamorphosis
1165 Failure in gamma-glutamyl carboxylation of clotting factors II, VII, IX and X, Under carbo leads to Hemostasis, Depletion from blood of fully functional carboxylated clotting factors
1166 Hemostasis, Depletion from blood of fully functional carboxylated clotting factors leads to Under carboxylated clotting factors will not assemble on cell surfaces to form clot, Failur
1167 Irreversible inhibition of hepatic VKOR by binding of AR at tyrosine 139, Failure to cycle leads to Failure in gamma-glutamyl carboxylation of clotting factors II, VII, IX and X, Under carbo
1168 Under carboxylated clotting factors will not assemble on cell surfaces to form clot, Failur leads to Failure in vascular repair mechanisms, Unresolved blood loss (hemorrhage)
1169 Failure in vascular repair mechanisms, Unresolved blood loss (hemorrhage) leads to Blood loss and development of anemia, Impaired oxygen delivery and nutrient delivery to tis
1170 Blood loss and development of anemia, Impaired oxygen delivery and nutrient delivery to tis leads to Reduced fitness or even mortality, Acidosis, hypovolemic shock and organ dysfunction
1171 Reduced fitness or even mortality, Acidosis, hypovolemic shock and organ dysfunction leads to Impaired recruitment , Population trajectory
1172 Increased, serotonin (5-HT) 1 leads to Increased, valve movement
1173 Increased, valve movement leads to Depletion, energy reserves
1174 Increased, valve movement leads to Increased, water retention in foot
1175 Increased, water retention in foot leads to Increased, foot detachment
1176 Increased, foot detachment leads to Depletion, energy reserves
1177 Increased, locomotion leads to Depletion, energy reserves
1178 Increase, cilia movement leads to premature, spawning 1
1179 premature, spawning 1 leads to Decreased, Reproductive Success
1180 Decreased, Reproductive Success leads to Decline, Population
1181 Depletion, energy reserves leads to Delayed, Sexual maturity
1182 Delayed, Sexual maturity leads to Decreased, Reproductive Success
1183 Increased, foot detachment leads to Increase, predation
1184 Increase, predation leads to Decline, Population
1185 Depletion, energy reserves leads to Increase, predation
1186 Increased, serotonin (5-HT) 1 leads to Decreased, gametogenesis
1187 Increase, cilia movement leads to premature, Spawning
1188 Decreased, gametogenesis leads to Decreased, Reproductive Success
1189 Increased, serotonin (5-HT) 1 leads to Increased, locomotion
1190 Increase, Incomplete ecdysis leads to Increased Mortality
1191 Increased Mortality leads to Decreased, Population size
1192 Increased, serotonin (5-HT) 1 leads to increased or inappropriate, mantel display
1193 increased or inappropriate, mantel display leads to Decreased, Reproductive Success
1194 Anticoagulant rodenticide interferes with gamma-carboxyglutamate formation, Inhibition of p leads to Calcium cannot bind to the hydroxyapatite matrix of bone, Osteocalcin and other bone protei
1195 Calcium cannot bind to the hydroxyapatite matrix of bone, Osteocalcin and other bone protei leads to Uncarboxylated osteocalcin not incorporated into bone matrix, decreasing bone strength, Imp
1196 Uncarboxylated osteocalcin not incorporated into bone matrix, decreasing bone strength, Imp leads to Osteoporosis and vascular calcification, Bone deterioration
1197 Inhibition, Iodotyrosine deiodinase (IYD) leads to Thyroidal Iodide, Decreased
1198 Inhibition, Deiodinase 1 leads to Decreased, Triiodothyronine (T3) in tissues
1199 Inhibition, Deiodinase 2 leads to Decreased, Triiodothyronine (T3) in tissues
1200 Inhibition, Deiodinase 3 leads to Increased, Triiodothyronine (T3) in tissues
1201 Increased, Triiodothyronine (T3) in tissues leads to Altered, Amphibian metamorphosis
1202 Inhibition, Pendrin leads to TH synthesis, Decreased
1203 Inhibition, Dual oxidase leads to TH synthesis, Decreased
1204 Activation, Hepatic nuclear receptor(s) leads to Increased, Hepatic thyroid hormone uptake/transport
1205 Activation, Hepatic nuclear receptor(s) leads to Induction, Upregulation of glucuronyltransferase activity
1206 Increased, Hepatic thyroid hormone uptake/transport leads to Increase, Biliary excretion TH glucuronide
1207 Increased, serotonin (5-HT) leads to Increased, mantel display
1208 Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) leads to Increased, cilia movement
1209 Increased, serotonin (5-HT) leads to Increased, cilia movement
1210 Increased, cilia movement leads to premature, Spawning
1211 premature, Spawning leads to Increased, Population
1212 Increased, serotonin (5-HT) leads to Increased, oocyte maturation
1213 Increased, oocyte maturation leads to Increased, Reproductive Success
1214 Increased, mantel display leads to Increased, Reproductive Success
1215 Increased, Reproductive Success leads to Increased, Population
1216 Increased, valve movement leads to Increased, water pumping
1217 Increase, cilia movement leads to Increased, water pumping
1218 Increase, cilia movement leads to Depletion, energy reserves
1219 increased or inappropriate, mantel display leads to Depletion, energy reserves
1220 increased or inappropriate, mantel display leads to induced, parturition
1221 induced, parturition leads to Decreased, Reproductive Success
1222 premature, Spawning leads to Decreased, Reproductive Success
1223 Increased, water retention in foot leads to Increased, valve movement
1224 Increased, water pumping leads to Increased, water retention in foot
1225 Increased, water pumping leads to premature, Spawning
1226 Increased, water pumping leads to induced, parturition
1227 Increased, valve movement leads to Increase, predation
1228 Increased, muscular waves in foot leads to Depletion, energy reserves
1229 Activation, PPARα leads to modulation, Genes/proteins that regulate hepatocyte fate
1230 modulation, Genes/proteins that regulate hepatocyte fate leads to Increase, Mitogenic cell proliferation (hepatocytes)
1231 modulation, Genes/proteins that regulate hepatocyte fate leads to Increase, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci
1232 Increase, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci leads to Increase, Adenomas/carcinomas (hepatocellular)
1233 Activation, PPARα leads to Increase, Genes involved in fatty acid oxidation
1234 Increase, Genes involved in fatty acid oxidation leads to Peptide Oxidation
1235 Activation, NADPH Oxidase leads to Peptide Oxidation
1236 Activation, PPARα leads to Activation, NADPH Oxidase
1237 Peptide Oxidation leads to Increase activation, Nuclear factor kappa B (NF-kB)
1238 Increase activation, Nuclear factor kappa B (NF-kB) leads to modulation, Genes/proteins that regulate hepatocyte fate
1239 Increase, Mitogenic cell proliferation (hepatocytes) leads to Increase, Clonal Expansion / Cell Proliferatin to form Pre-Neoplastic Altered Hepatic Foci
1240 Increase, Genes involved in fatty acid oxidation leads to Increase, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids
1241 Increase, Peroxisomal Fatty Acid Beta Oxidation of Fatty Acids leads to Peptide Oxidation
1242 Inhibition, sodium channel leads to Decreased, sodium conductance 2
1243 Decreased, sodium conductance 2 leads to Decreased, Ionotropic GABA receptor chloride channel conductance
1244 Decreased, sodium conductance 2 leads to Decreased, GABA release
1245 Decreased, GABA release leads to Decreased, Chloride conductance
1246 Activation, Estrogen receptor leads to Increased, ER binding to DNA (classical pathway)
1247 Increase, Cell Proliferation (Epithelial Cells) leads to Increased, Ductal Hyperplasia
1248 Decreased, Apoptosis (Epithelial Cells) leads to Increased, Ductal Hyperplasia
1249 Activation, Estrogen receptor leads to Increased, ER binding to T.F. to DNA (non-classical pathway)
1250 Increased, ER binding to DNA (classical pathway) leads to Increase, Cell Proliferation (Epithelial Cells)
1251 Increased, ER binding to T.F. to DNA (non-classical pathway) leads to Increase, Cell Proliferation (Epithelial Cells)
1252 Increased, Ductal Hyperplasia leads to N/A, Breast Cancer
1253 Binding, Immunophilins leads to Inhibition, Calcineurin Activity
1254 Inhibition, Calcineurin Activity leads to Suppression, IL-2 and IL-4 production
1255 Suppression, IL-2 and IL-4 production leads to Interference, nuclear localization of NFAT
1256 Reduction, NFAT/AP-1 complex formation leads to Suppression, Suppression of production of cytotoxic T-cells
1257 Reduction, NFAT/AP-1 complex formation leads to Suppression, Suppression of T-cell dependent antibody production
1258 Suppression, Suppression of production of cytotoxic T-cells leads to Impairment, T-cell dependent antibody response
1259 Suppression, Suppression of T-cell dependent antibody production leads to Increase, Increased susceptibility to infection
1260 Suppression, Suppression of production of cytotoxic T-cells leads to Increase, Increased susceptibility to infection
1261 Activation, Juvenile hormone receptor leads to Induction, Doublesex1 gene
1262 Induction, Doublesex1 gene leads to Induction, Male reproductive tract
1263 Induction, Male reproductive tract leads to Increased, Male offspring
1264 Increased, Male offspring leads to Decline, Population
1265 Decline, Population leads to Alteration, Food-web structures
1266 Increased, Proliferation (Endothelial cells) leads to Increased, Angiogenesis
1267 Increased, Migration (Endothelial Cells) leads to Increased, Angiogenesis
1268 Activation, Constitutive androstane receptor leads to Altered expression of hepatic CAR-dependent genes
1269 Altered expression of hepatic CAR-dependent genes leads to Increase, Mitogenic cell proliferation (hepatocytes)
1271 TRPA1 activation, TRPA1 Receptor leads to Opening of calcium channel, Calcium influx
1272 Opening of calcium channel, Calcium influx leads to Sensory Airway Irritation
1273 Sensory Airway Irritation leads to Cough, Dyspnea, Sneezing, Acute respiratory effect
1274 Opening of calcium channel, Calcium influx leads to Excitation, Trigeminal nerve excitation
1275 Excitation, Trigeminal nerve excitation leads to Cough, Dyspnea, Sneezing, Acute respiratory effect
1276 Excitation, Trigeminal nerve excitation leads to Increased Airway Hyper-responsiveness,Cough, Dyspnea
1277 Non-neuronal production of TNF, Epithelial irritation leads to Leukocyte infiltration
1278 Leukocyte infiltration leads to Respiratory irritability
1279 SP (Substance P) release, Local increase of SP leads to Non-neuronal production of TNF, Epithelial irritation
1280 Opening of calcium channel, Calcium influx leads to SP (Substance P) release, Local increase of SP
1281 TRPV1 activation, TRPV1 leads to Opening of calcium channel, Calcium influx
1282 Oxidization of biomolecules, Lipid bilayer and cellular proteins leads to TRPA1 activation, TRPA1 Receptor
1283 Production of nerve growth factor , Epithelial irritation leads to SP (Substance P) release, Local increase of SP
1284 TRPA1 activation, TRPA1 Receptor leads to Non-neuronal production of IL-8/CXCL1, Epithelial irritation
1285 Oxidization of biomolecules, Lipid bilayer and cellular proteins leads to Generation of novel epitopes , Antigen presentation
1286 Oxidization of biomolecules, Lipid bilayer and cellular proteins leads to Production of nerve growth factor , Epithelial irritation
1287 Non-neuronal production of IL-8/CXCL1, Epithelial irritation leads to Opening of calcium channel, Calcium influx
1288 Non-neuronal production of TNF, Epithelial irritation leads to Opening of calcium channel, Calcium influx
1289 Generation of novel epitopes , Antigen presentation leads to Sensitization, Immune system
1290 Leukocyte infiltration leads to Sensitization, Immune system
1291 Oxidation leads to Generation of novel epitopes , Antigen presentation
1292 Oxidation leads to TRPA1 activation, TRPA1 Receptor
1293 Oxidation leads to Production of nerve growth factor , Epithelial irritation
1294 Activation, Estrogen receptor leads to Increased, Non-genomic signaling
1295 Increased, Non-genomic signaling leads to Increased, ER binding to T.F. to DNA (non-classical pathway)
1296 Increased, ER binding to DNA (classical pathway) leads to Altered, Gene Expression
1297 Increased, ER binding to T.F. to DNA (non-classical pathway) leads to Altered, Gene Expression
1298 Altered, Gene Expression leads to Altered, Protein Production
1299 Altered, Protein Production leads to Increased, Oxidative Stress
1300 Increased, Oxidative Stress leads to Increase, DNA Damage
1301 Increase, DNA Damage leads to Altered, Gene Expression
1302 Increased, Non-genomic signaling leads to Altered, Gene Expression
1303 Altered, Protein Production leads to Increased, Proliferation (Endothelial cells)
1304 Altered, Protein Production leads to Decreased, Apoptosis (Epithelial Cells)
1305 Altered, Protein Production leads to Increased, Motility
1306 Increased, Motility leads to Increased, Invasion
1307 Activation, Estrogen receptor leads to Increased, Second Messenger Production
1308 Increased, Second Messenger Production leads to Increased, Non-genomic signaling
1309 Desensitization, Nicotinic acetylcholine receptor leads to Altered, Ca2+-calmodulin activated signal transduction
1310 Altered, Ca2+-calmodulin activated signal transduction leads to Impairment, Learning and memory
1311 N/A, Mitochondrial dysfunction 1 leads to Altered, Ca2+-calmodulin activated signal transduction
1312 Goblet cell hyperplasia leads to Increase, Mucin production
1313 Occurrence, Metaplasia of goblet cells leads to Increase, Mucin production
1314 Chronic, Mucus hypersecretion leads to Decrease, Lung function
1315 Increase, Mucin production leads to Chronic, Mucus hypersecretion
1316 Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) leads to Increased, muscular waves in foot
1317 Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) leads to Increased, valve movement
1318 Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) leads to Increase, cilia movement
1319 Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) leads to increased mantel display
1320 Increased, valve movement leads to induced spawning
1321 Increase, cilia movement leads to induced spawning
1322 increased mantel display leads to Induced parturition
1323 Induced parturition leads to Decreased, Reproductive Success
1324 induced spawning leads to Decreased, Reproductive Success
1325 induced spawning leads to Increased, Reproductive Success
1326 Induced parturition leads to Increased, Reproductive Success
1327 Increased, serotonin (5-HT) leads to Increased, valve movement
1328 Increased, oocyte maturation leads to induced spawning
1329 Increased, cilia movement leads to induced spawning
1330 Binding, topoisomerase II leads to MLL translocation
1331 MLL translocation leads to IFL
1332 Increased, serotonin (5-HT) leads to Increased, muscular waves in foot
1333 Increased, serotonin (5-HT) leads to Increase, cilia movement
1334 Increased, valve movement leads to Induced parturition
1335 Increase, cilia movement leads to Induced parturition
1336 Increased, serotonin (5-HT) leads to increased mantel display
1337 Inhibition, 5-hydroxytryptamine transporter (5-HTT; SERT) leads to Increased, oocyte maturation
1338 Decompartmentalization leads to Mitochondrial impairment
1339 Direct mitochondrial inhibition leads to Mitochondrial impairment
1340 narcosis leads to Mitochondrial impairment
1341 Mitochondrial impairment leads to Apoptosis
1342 Mitochondrial impairment leads to Necrosis
1343 Increase, EcR agonism leads to Increase, E75b expression
1344 Increase, E75b expression leads to Increase, Ftz-f1 expression
1345 Increase, Ftz-f1 expression leads to Decrease, Circulating ETH
1346 Decrease, Circulating ETH leads to Decrease, Circulating CCAP
1347 Decrease, Circulating CCAP leads to Decrease, Ecdysis motoneuron bursts
1348 Decrease, Ecdysis motoneuron bursts leads to Decrease, Excitatory postsynaptic potential
1349 Decrease, Excitatory postsynaptic potential leads to Decrease, Abdominal muscle contraction
1350 dimerization, AHR/ARNT leads to Increase, COX-2 expression
1351 Increase, COX-2 expression leads to Altered, Cardiovascular development/function
1352 Altered, Cardiovascular development/function leads to Increase, Mortality
1353 Inactivation of PPARγ leads to Activation of TGF-β signaling
1354 Activation of TGF-β signaling leads to Differentiation of Myofibroblast
1355 Activation of TGF-β signaling leads to Expression of Collagen
1356 Differentiation of Myofibroblast leads to Production of α-smooth muscle actin
1357 Expression of Collagen leads to Collagen Deposition
1358 Production of α-smooth muscle actin leads to Lung fibrosis
1359 Collagen Deposition leads to Lung fibrosis
1360 Activation, NADPH Oxidase leads to ROS formation
1361 ROS formation leads to Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK
1362 Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK leads to Increased, DNA Damage-Repair
1363 Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK leads to Damaging, Mitochondria
1364 Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK leads to Activation, HIF-1
1365 Activation, HIF-1 leads to Apoptosis
1366 Increased, DNA Damage-Repair leads to Apoptosis
1367 Damaging, Mitochondria leads to Apoptosis
1368 Apoptosis leads to Reproductive failure
1369 Activation, JAK/STAT pathway leads to Activation, TGF-beta pathway
1370 Activation, TGF-beta pathway leads to Reproductive failure
1371 Up Regulation, SREBF2 leads to Up Regulation, Unsaturated fatty acid
1372 Up Regulation, Unsaturated fatty acid leads to Perturbation of cholesterol
1373 Down Regulation, GSS and GSTs gene leads to Glutathione synthesis
1374 Glutathione synthesis leads to Activation, 3-hydroxy-3-methylglutaryl-CoA reductase gene
1375 Activation, 3-hydroxy-3-methylglutaryl-CoA reductase gene leads to Perturbation of cholesterol
1376 Down Regulation, GSS and GSTs gene leads to Glutathione homeostasis
1377 Perturbation of cholesterol leads to Hepatotoxicity
1378 Glutathione homeostasis leads to Hepatotoxicity
1379 Peptide Oxidation leads to Activation, JNK
1380 Activation, JNK leads to Activation, FOXO
1381 Activation, FOXO leads to Inhibition, Wnt pathway
1382 Inhibition, Wnt pathway leads to Defect of Embryogenesis
1383 Defect of Embryogenesis leads to Reproductive failure
1384 Agonism, Androgen receptor leads to Reduction, 17beta-estradiol synthesis by ovarian granulosa cells
1385 Agonism, Androgen receptor leads to Reduction, Vitellogenin synthesis in liver
1386 Reduction, Plasma 17beta-estradiol concentrations leads to Reduction, Plasma vitellogenin concentrations
1387 T4 in serum, Decreased leads to Hippocampal gene expression, Altered
1388 T4 in serum, Decreased leads to Hippocampal anatomy, Altered
1389 T4 in serum, Decreased leads to Hippocampal Physiology, Altered
1390 Increase, insulin leads to Activation, insulin receptor
1391 Activation, insulin receptor leads to Activation, mTORC2
1392 Activation, mTORC2 leads to Activation, AKT
1393 Activation, mTORC2 leads to Activation, mTORC1
1394 Activation, AKT leads to Activation, SREBP-1
1395 Activation, mTORC1 leads to Activation, L-FABP
1396 Activation, mTORC1 leads to Activation, HSD17B4
1397 Activation, SREBP-1 leads to Activation, FXR
1398 Activation, AKT leads to Activation, mTORC1
1399 Activation, mTORC1 leads to Activation, SREBP-1
1400 Activation, AKT leads to Activation, L-FABP
1401 Activation, L-FABP leads to Increase, cytosolic fatty acid
1402 demethylation, PPARg promoter leads to Activation, SREBP-1
1403 Activation, SREBP-1 leads to Activation, SCD-1
1404 Activation, SCD-1 leads to Increased, lipogenesis
1405 Increased, lipogenesis leads to Increase, cytosolic fatty acid
1406 Activation, NRF2 leads to Activation, FXR
1407 Activation, FXR leads to Activation, SHP
1408 Activation, FXR leads to Activation, PPARα
1409 Activation, SHP leads to Activation, PPARα
1410 Activation, PPARα leads to Activation, HSD17B4
1411 Activation, HSD17B4 leads to Inhibition, Mitochondrial fatty acid beta-oxidation
1412 Activation, SHP leads to Inhibition, LXR
1413 Inhibition, LXR leads to Inhibition, PPAR alpha
1414 Activation, SHP leads to Inhibition, LRH-1
1415 Activation, HSD17B4 leads to Induction, fatty acid beta-oxidation
1416 Induction, fatty acid beta-oxidation leads to Inhibition, Steatosis
1417 Induction, fatty acid beta-oxidation leads to Decrease, cytosolic fatty acid
1418 Activation, PI3K leads to Activation, AKT
1419 Activation, PI3K leads to Activation, L-FABP
1420 Activation, PI3K leads to Activation, aPKC
1421 Activation, aPKC leads to Activation, SREBP-1
1422 Activation, FAS leads to Increased, lipogenesis
1423 Activation, L-FABP leads to demethylation, PPARg promoter
1424 demethylation, PPARg promoter leads to Activation, FAS
1425 Activation, LRH-1 leads to Activation, FAS
1426 Decreased, serotonin transporter activity leads to Increased, intracellular sodium (Na+)
1427 Decreased, serotonin transporter activity leads to Increased, intracellular chloride (Cl-)
1428 Decreased, serotonin transporter activity leads to Decreased, extracellular Na+
1429 Decreased, serotonin transporter activity leads to Decreased, extracellular chloride (Cl-)
1430 Decreased, serotonin transporter activity leads to Increased, extracellular serotonin
1431 Decreased, serotonin transporter activity leads to Decreased, intracellular serotonin
1432 Decreased, intracellular serotonin leads to Decreased, packaged serotonin
1433 Decreased, packaged serotonin leads to Decreased, synaptic release
1434 Decreased, synaptic release leads to Decreased, extracellular serotonin
1435 Decreased, extracellular serotonin leads to Increased, 5-HT3
1436 Decreased, extracellular serotonin leads to Inactivated, 5-HTR
1437 Decreased, extracellular serotonin leads to Activation, 5-HT2A
1438 Activation, 5-HT2A leads to Activate, PLC
1439 Activate, PLC leads to Increase, inositol triphosphate
1440 Increase, inositol triphosphate leads to Increase, intracellular calcium
1441 Increase, intracellular calcium leads to Activate, calmodulin
1442 Activate, calmodulin leads to Increase, myosin light chain phosphorylation
1443 Increase, myosin light chain phosphorylation leads to Increase, vascular smooth muscle contraction
1444 Increase, vascular smooth muscle contraction leads to Increase, hypertension
1445 Increased, 5-HT3 leads to Increased, seizure
1446 Inactivated, 5-HTR leads to Reduce expression, BDNF
1447 Reduce expression, BDNF leads to Decreased, neuroplasticity
1448 Decreased, neuroplasticity leads to Increased, agitation
1449 Decreased, neuroplasticity leads to Increased, depression
1450 Increase, cortisone leads to Activation, Glucocorticoid Receptor
1451 Activation, Glucocorticoid Receptor leads to Reduced, BDNF
1452 Activated, presynaptic neuron 1 leads to Increased, glutamate
1453 Increased, glutamate leads to Activated, NMDA receptor
1454 Activated, NMDA receptor leads to Increased, intracellular sodium (Na+)
1455 Increased, intracellular sodium (Na+) leads to Activated, voltage-gated sodium channel
1456 Treat, carbamazepine leads to Inhibit, voltage-gated sodium channel
1457 Activated, voltage-gated sodium channel leads to Activated, membrane depolarization
1458 Activated, membrane depolarization leads to Increased, hippocampal hyperdepolarization
1459 Increased, hippocampal hyperdepolarization leads to Increase, seizure
1460 Increase, seizure leads to Increased, epilepsy
1461 Activate, presynaptic neuron 2 leads to Increase, GABA
1462 Increase, GABA leads to Activate, GABA-A receptor
1463 Increased, RDX dose leads to Activate, GABA-A receptor
1464 Activate, GABA-A receptor leads to Increased, intracellular chloride (Cl-)
1465 Increased, intracellular chloride (Cl-) leads to Inactive, membrane depolarization
1466 Increase, ROS leads to Peptide Oxidation
1467 Peptide Oxidation leads to Increase, DNA Damage
1468 Increase, DNA Damage leads to Increase, Apoptosis
1469 Increase, Apoptosis leads to Decrease, Oogenesis
1470 Decrease, Oogenesis leads to Decrease, Ovulation
1471 Decrease, Ovulation leads to Decrease, Fertility
1472 Decrease, Fertility leads to Decrease, Population trajectory
1473 Increase, angiogenesis leads to Inhibit, gastric ulcer formation
1474 Increase, platelet aggregation leads to Inhibit, gastric ulcer formation
1475 Activate, mucosal defense leads to Inhibit, gastric ulcer formation
1476 Activate, leukocyte leads to Activated, gastric ulcer formation
1477 Increase, leukocyte adherence leads to Activate, leukocyte
1478 Activation, PTGS-2 leads to Decrease, leukocyte adherence
1479 Activation, PTGS-2 leads to Increase, angiogenesis
1480 Activation, PTGS-1 leads to Increase, platelet aggregation
1481 Activation, PTGS-1 leads to Increase, mucosal blood flow
1482 Activation, PTGS-1 leads to Increase, mucous
1483 Activation, PTGS-1 leads to Increase, bicarbonate
1484 Increase, bicarbonate leads to Activate, mucosal defense
1485 Increase, mucous leads to Activate, mucosal defense
1486 Increase, mucosal blood flow leads to Activate, mucosal defense
1487 Increase, ammonium (NH4+) leads to Decrease, surfactant
1488 Activate, phospholipase leads to Decrease, surfactant
1489 Increase, surfactant leads to Activate, mucosal defense
1491 Decreased, Population trajectory leads to Increased Mortality
1493 CYP7B activity, inhibition leads to 7α-hydroxypregnenolone synthesis in the brain, decreased
1494 CYP7B activity, inhibition leads to Locomotor activity, decreased
1495 7α-hydroxypregnenolone synthesis in the brain, decreased leads to Locomotor activity, decreased
1496 7α-hydroxypregnenolone synthesis in the brain, decreased leads to Dopamine release in the brain, decreased
1497 Dopamine release in the brain, decreased leads to Locomotor activity, decreased
1498 7α-hydroxypregnenolone synthesis in the brain, decreased leads to Sexual behavior, decreased
1499 Sexual behavior, decreased leads to Decreased, Reproductive Success
1500 Locomotor activity, decreased leads to Decreased, Reproductive Success
1501 Decreased, Reproductive Success leads to Decreased, Population trajectory
1502 Dopamine release in the brain, decreased leads to Sexual behavior, decreased
1503 Inhibition, Na+/I- symporter (NIS) leads to Impairment, Learning and memory
1504 TH synthesis, Decreased leads to BDNF, Reduced
1505 TH synthesis, Decreased leads to GABAergic interneurons, Decreased
1506 TH synthesis, Decreased leads to Impairment, Learning and memory
1507 BDNF, Reduced leads to Impairment, Learning and memory
1508 Inhibition, Calcineurin Activity leads to Interference, nuclear localization of NFAT
1509 Reduction, NFAT/AP-1 complex formation leads to Suppression, IL-2 and IL-4 production
1510 Suppression, IL-2 and IL-4 production leads to Impairment, T-cell dependent antibody response
1511 Inactivated, 5-HTR leads to Reduced, BDNF
1512 Activation of Cyp2E1 leads to Oxidative Stress
1513 Oxidative Stress leads to Hepatocytotoxicity
1514 Hepatocytotoxicity leads to Sustained proliferation
1515 Activation of Cyp2E1 leads to Hepatocytotoxicity
1516 Oxidative Stress leads to Liver Cancer
1517 Hepatocytotoxicity leads to Liver Cancer
1518 Sustained proliferation leads to Liver Cancer
1519 Decreased, extracellular serotonin leads to Decreased, synaptic release
1520 Inhibit, serotonin transporter activity leads to Decreased, serotonin transporter activity
1521 Increased, extracellular serotonin leads to Decreased, extracellular serotonin
1522 Increased, glucocorticoid receptor activity leads to Reduced, BDNF
1523 Reduced, BDNF leads to Decreased, neuroplasticity
1524 Increased, serotonin transporter activity leads to Increased, intracellular serotonin
1525 Increased, intracellular serotonin leads to Increased, packaged serotonin
1526 Increased, packaged serotonin leads to Increased, synaptic release
1527 Increased, synaptic release leads to Increased, extracellular serotonin
1528 Increased, serotonin transporter activity leads to Decreased, extracellular serotonin
1529 Increased, extracellular serotonin leads to Decreased, 5-HT3
1530 Decreased, 5-HT3 leads to Increased, seizure
1531 Increased, extracellular serotonin leads to Activation, 5-HT2A
1532 Reduced, PTGS1 function leads to Reduced, platelet aggregation
1533 Reduced, platelet aggregation leads to Activated, gastric ulcer formation
1534 Reduced, PTGS1 function leads to Decreased, mucosal blood flow
1535 Decreased, mucosal blood flow leads to Reduced, mucosal defense
1536 Reduced, mucosal defense leads to Activated, gastric ulcer formation
1537 Reduced, PTGS1 function leads to Decreased, mucous
1538 Decreased, mucous leads to Reduced, mucosal defense
1539 Reduced, PTGS1 function leads to Decreased, bicarbonate
1540 Decreased, bicarbonate leads to Reduced, mucosal defense
1541 Reduced, PTGS2 function leads to Decreased, angiogenesis
1542 Decreased, angiogenesis leads to Activated, gastric ulcer formation
1543 Reduced, PTGS2 function leads to Increased, leukocyte adherence
1544 Increased, leukocyte adherence leads to Increased, leukocyte activation
1545 Increased, leukocyte activation leads to Activated, gastric ulcer formation
1546 Helicobacter pylori infection leads to Increase, ammonium (NH4+)
1547 Decrease, surfactant leads to Reduced, mucosal defense
1548 Reduced, mucosal defense leads to Helicobacter pylori infection
1549 Increased, hippocampal hyperdepolarization leads to Increased, seizure
1550 Increased, seizure leads to Increased, epilepsy
1551 Reduced, presynaptic neuron 2 activity leads to Decreased, GABA
1552 Decreased, GABA leads to Reduced, GABA-A receptor activation
1553 Reduced, GABA-A receptor activation leads to Decreased, intracellular chloride
1554 Decreased, intracellular chloride leads to Activated, membrane depolarization
1555 Increased, RDX dose leads to Reduced, GABA-A receptor activation
1556 NFE2/Nrf2 repression leads to Reduced, FXR activity
1557 Reduced, FXR activity leads to Reduced, SHP activity
1558 Reduced, SHP activity leads to Activated, LXR
1559 Activated, LXR leads to Reduced, PPARalpha
1560 Reduced, PPARalpha leads to Reduced, HSD17B4 activity
1561 Reduced, HSD17B4 activity leads to Reduced, fatty acid beta oxidation
1562 Reduced, fatty acid beta oxidation leads to Increased, steatosis
1563 Mu Opioid Receptor Agonism leads to Release of G Proteins
1564 Release of G Proteins leads to Opening of GIRK channels
1565 Opening of GIRK channels leads to hyperpolarisation, neuron
1566 hyperpolarisation, neuron leads to Analgesia
1567 Altered, Cardiovascular development/function leads to Increase, Early Life Stage Mortality
1568 Release of G Proteins leads to Inhibition of Ca Channels
1569 Inhibition of Ca Channels leads to Inhibition of neurotransmitter release
1570 Inhibition of neurotransmitter release leads to Analgesia
1571 Serotonin 1A Receptor Agonism leads to Release of G Proteins
1572 hyperpolarisation, neuron leads to Anti-depressant Activity
1573 Inhibition of neurotransmitter release leads to Anti-depressant Activity
1574 SP (Substance P) release, Local increase of SP leads to Increased Airway Hyper-responsiveness,Cough, Dyspnea
1575 Excitation, Trigeminal nerve excitation leads to SP (Substance P) release, Local increase of SP
1576 TRPA1 activation, TRPA1 Receptor leads to Generation of novel epitopes , Antigen presentation
1577 SP (Substance P) release, Local increase of SP leads to Leukocyte infiltration
1578 Excitation, Trigeminal nerve excitation leads to Increased CGRP
1579 Increased CGRP leads to Increased Airway Hyper-responsiveness,Cough, Dyspnea
1580 Increased CGRP leads to Increase, hypertension
1581 Increase, hypertension leads to Respiratory irritability
1582 Excitation, Trigeminal nerve excitation leads to Irritation induced sneezing
1583 Excitation, Trigeminal nerve excitation leads to Increased NKA
1584 Increased NKA leads to Increased Airway Hyper-responsiveness,Cough, Dyspnea
1585 Increased NKA leads to Leukocyte infiltration
1586 Increased CGRP leads to Leukocyte infiltration
1587 Increased CGRP leads to Respiratory irritability
1588 Sensing of the stressor leads to Pro-inflammatory cytokines increased
1589 Pro-inflammatory cytokines increased leads to SAA production increased
1590 SAA production increased leads to HDL-SAA formation
1591 HDL-SAA formation leads to Systemic cholesterol increased
1592 Systemic cholesterol increased leads to Foam cell formation
1593 HDL-SAA formation leads to Foam cell formation
1594 Foam cell formation leads to Plaque progression
1595 Increase, ROS leads to Increase, DNA Damage
1596 Increase, Apoptosis leads to Increase, Follicular atresia
1597 Increase, Follicular atresia leads to Decrease, Oogenesis
1598 Increase, ROS leads to Increase, LPO
1599 Increase, LPO leads to Increase, Uncoupling of OXPHOS
1600 Increase, Uncoupling of OXPHOS leads to Decrease, Mitochondrial ATP production
1601 Decrease, Mitochondrial ATP production leads to Decrease, Oogenesis
1602 Increase, ROS production leads to Increase, DNA Damage
1603 Increase, ROS production leads to Increase, LPO
1606 Activation, LXR alpha leads to Increased, De Novo FA synthesis
1607 Increased, De Novo FA synthesis leads to Increased, Liver Steatosis
1608 demethylation, PPARg promoter leads to Activation of specific nuclear receptors, PPAR-gamma activation
1609 Activation of specific nuclear receptors, PPAR-gamma activation leads to increased adipogenesis
1610 activation of CEBPA leads to Activation of specific nuclear receptors, PPAR-gamma activation
1611 activation of CEBPA leads to increased adipogenesis
1612 increased adipogenesis leads to obesity
1613 chronic high fat diet leads to decreased dopamine
1614 decreased dopamine leads to decreased reward
1615 decreased reward leads to decreased DNA methylation of tyrosine hydroxylase
1616 decreased reward leads to decreased methylation of dopamine transporter promoter
1617 decreased reward leads to decreased dopamine
1618 decreased DNA methylation of tyrosine hydroxylase leads to obesity
1619 decreased methylation of dopamine transporter promoter leads to obesity
1620 decreased DNA methylation of tyrosine hydroxylase leads to decreased dopamine
1621 decreased methylation of dopamine transporter promoter leads to decreased dopamine
1622 Sustained inflammatory cytokine release leads to Increased, secretion of local growth factors
1623 Increase, ROS production leads to Increased, secretion of local growth factors
1624 Increased, secretion of local growth factors leads to Differentiation of fibroblasts
1625 Increased, secretion of local growth factors leads to EMT
1626 Differentiation of fibroblasts leads to Expression of Collagen
1627 EMT leads to Expression of Collagen
1628 Collagen Deposition leads to Accumulation, Collagen
1629 Accumulation, Collagen leads to Pulmonary fibrosis
1630 Cell damage sensing leads to Sustained inflammatory cytokine release
1631 Cell damage sensing leads to Increase, ROS production
1632 Cell damage sensing leads to Increased, secretion of local growth factors
1633 Sustained inflammatory cytokine release leads to Differentiation of fibroblasts
1634 Binding, topoisomerase II leads to DSB
1635 DSB leads to MLL translocation
1636 Thiol protein adducts leads to Inhibition of lysyl oxidase
1637 Inhibition of lysyl oxidase leads to Reduction of collagen crosslinking
1638 Reduction of collagen crosslinking leads to Weak collagen matrix
1639 Weak collagen matrix leads to Notochord malformation
1640 Notochord malformation leads to Reduced, Swimming performance
1641 Reduced, Swimming performance leads to Growth, reduction
1642 Reduced, Swimming performance leads to Decreased, survival
1643 Decrease, histaminergic neuron excitation leads to Impairment, Learning and memory
1644 Impairment, Learning and memory leads to Decreased, locomotion
1645 GR Agonist, Activation leads to Increased apoptosis, decreased Leydig Cells
1646 GR Agonist, Activation leads to Repressed expression of steroidogenic enzymes
1647 Increased apoptosis, decreased Leydig Cells leads to Reduction, Testosterone synthesis in Leydig cells
1648 Repressed expression of steroidogenic enzymes leads to Reduction, Testosterone synthesis in Leydig cells
1649 Reduction, testosterone level leads to Decreased sperm quantity or quality in the adult, Decreased fertility
1650 Decreased sperm quantity or quality in the adult, Decreased fertility leads to impaired, Fertility
1651 TGFbeta1 activation leads to TGFbeta pathway activation
1652 TGFbeta pathway activation leads to Differentiation of fibroblasts
1653 TGFbeta pathway activation leads to EMT
1654 Differentiation of fibroblasts leads to Accumulation, Collagen
1655 EMT leads to Accumulation, Collagen
1656 Activation, AhR leads to Up Regulation, SCD-1
1657 Up Regulation, SCD-1 leads to Accumulation, Triglyceride
1658 Increased, FA Influx leads to Increased, Triglyceride formation
1659 demethylation, PPARg promoter leads to Increased, FA Influx
1660 Decreased, Ketogenesis leads to Accumulation, Fatty acid
1661 Activation, AKT2 leads to Activation, SREBF1
1662 Activation, SREBF1 leads to Increased, Liver Steatosis
1663 Increase, Uncoupling of photophosphorylation leads to Decrease, Chloroplast ATP production
1664 Decrease, Chloroplast ATP production leads to Decrease, Chlorophyll synthesis
1665 Decrease, Chlorophyll synthesis leads to Decrease, Light harvest capacity
1666 Decrease, Light harvest capacity leads to Decrease, Photosynthesis
1667 Decrease, Photosynthesis leads to Decrease, Glycolysis
1668 Decrease, Glycolysis leads to Decrease, OXPHOS
1669 Decrease, OXPHOS leads to Decrease, Mitochondrial ATP production
1670 Decrease, Mitochondrial ATP production leads to Decrease, Leaf cell mitosis
1671 Decrease, Leaf cell mitosis leads to Decrease, Leaf development
1672 Decrease, Leaf development leads to Increase, Growth inhibition
1673 Inhibition, mitochondrial DNA polymerase gamma (Pol gamma) leads to Depletion, mtDNA
1674 Depletion, mtDNA leads to Dysfunction, Mitochondria
1675 Dysfunction, Mitochondria leads to Increase, Cytotoxicity (renal tubular cell)
1676 Increase, Cytotoxicity (renal tubular cell) leads to Occurrence, Kidney toxicity
1677 Binding of substrate, endocytic receptor leads to Disturbance, Lysosomal function
1678 Disturbance, Lysosomal function leads to Disruption, Lysosome
1679 Disruption, Lysosome leads to Increase, Cytotoxicity (renal tubular cell)
1680 Alkylation, Protein leads to Dysfunction, Mitochondria
1681 Dysfunction, Mitochondria leads to Decrease, Mitochondrial ATP production
1682 Decrease, Mitochondrial ATP production leads to Increase, Cytotoxicity (renal tubular cell)
1683 Binding, SH/SeH proteins involved in protection against oxidative stress leads to N/A, Mitochondrial dysfunction 1
1684 N/A, Mitochondrial dysfunction 1 leads to Oxidative Stress
1685 Oxidative Stress leads to Glutamate dyshomeostasis
1686 Glutamate dyshomeostasis leads to Cell injury/death
1687 Neuroinflammation leads to Cell injury/death
1688 Cell injury/death leads to Neuronal network function, Decreased
1689 Binding, SH/SeH proteins involved in protection against oxidative stress leads to Oxidative Stress
1690 Oxidative Stress leads to Cell injury/death
1691 Glutamate dyshomeostasis leads to Neuronal network function, Decreased
1692 Inhibition of fatty acid beta oxidation leads to Increase, cytosolic fatty acid
1693 Increase, cytosolic fatty acid leads to steatohepatitis
1694 Increase, cytosolic fatty acid leads to Increased, Liver Steatosis
1695 Increased, Liver Steatosis leads to Increased, Reactive oxygen species
1696 Increased, Reactive oxygen species leads to increased, oncotic necrosis
1697 increased, oncotic necrosis leads to steatohepatitis
1698 Peptide Oxidation leads to S-Glutathionylation, eNOS
1699 Activation, Inflammatory cytokines, chemokines, cytoprotective gene pathways leads to Activation, Dendritic Cells
1700 N/A, Covalent binding to protein, possibly lysine residue leads to Activation, Dendritic Cells
1701 Activation/Proliferation, T-cells leads to Increase, Allergic Respiratory Hypersensitivity Response
1702 Interaction with the lung cell membrane leads to Increased proinflammatory mediators
1703 Increased proinflammatory mediators leads to Recruitment of inflammatory cells
1704 Recruitment of inflammatory cells leads to Loss of alveolar capillary membrane integrity
1705 Loss of alveolar capillary membrane integrity leads to Activation of Th2 cells
1706 Activation of Th2 cells leads to Increased cellular proliferation and differentiation
1707 Increased cellular proliferation and differentiation leads to Increased extracellular matrix deposition
1708 Increased extracellular matrix deposition leads to Pulmonary fibrosis
1709 Histone deacetylase inhibition leads to Histone acetylation, increase
1710 Histone acetylation, increase leads to p21 (CDKN1A) expression, increase
1711 p21 (CDKN1A) expression, increase leads to Cell cycle, disrupted
1712 Cell cycle, disrupted leads to Apoptosis
1713 Apoptosis leads to Testicular atrophy
1714 Histone deacetylase inhibition leads to p21 (CDKN1A) expression, increase
1715 Histone deacetylase inhibition leads to Cell cycle, disrupted
1716 Histone deacetylase inhibition leads to Apoptosis
1717 Histone deacetylase inhibition leads to Testicular atrophy
1718 Cell injury/death leads to Tissue resident cell activation
1719 Increased pro-inflammatory mediators leads to Cell injury/death
1720 Activation of PPARγ leads to Increase, Inflammation
1721 Activation of TGF-β signaling leads to Increase, Inflammation
1722 Increase, Inflammation leads to Expression of Collagen
1723 Activation of TGF-β signaling leads to EMT
1724 Increase, Inflammation leads to EMT
1725 EMT leads to Lung fibrosis
1726 CYP2E1 Activation leads to Oxidative Stress in Brain
1727 Oxidative Stress in Brain leads to Lipid Peroxidation
1728 Lipid Peroxidation leads to Protein Adduct Formation
1729 Protein Adduct Formation leads to Unfolded Prortein Response
1730 Oxidative Stress in Brain leads to Unfolded Prortein Response
1731 Lipid Peroxidation leads to General Apoptosis
1732 Unfolded Prortein Response leads to General Apoptosis
1733 General Apoptosis leads to Neurodegeneration
1734 Spermatocyte depletion leads to Testicular atrophy
1735 Apoptosis leads to Spermatocyte depletion
1736 Increase, D1 protein antagonism leads to Decrease, PSII activity
1737 Decrease, PSII activity leads to Decrease, Photosynthesis
1738 Decrease, Glycolysis leads to Decrease, Mitochondrial ATP production
1739 Decrease, Mitochondrial ATP production leads to Decrease, Growth
1740 Decrease, PSII activity leads to Increase, ROS
1741 Increase, Apoptosis leads to Decrease, Growth
1742 Increase, CHS inhibition leads to Decrease, Cuticular chitin synthesis
1743 Decrease, Cuticular chitin synthesis leads to Increase, Premature molting
1744 Increase, Premature molting leads to Increase, Mortality
1745 Increase, SUR binding leads to Increase, Cell membrane depolarization
1746 Increase, Cell membrane depolarization leads to Increase, Opening of voltage-dependent calcium channel
1747 Increase, Opening of voltage-dependent calcium channel leads to Decrease, Cuticular chitin synthesis
1748 Decreased, PPARalpha transactivation of gene expression leads to Fatty Acid Beta Oxidation, Decreased
1749 Fatty Acid Beta Oxidation, Decreased leads to Decreased, Ketogenesis (production of ketone bodies)
1750 Decrease, Mitochondrial ATP production leads to Increase, Apoptosis
1751 Increase, Apoptosis leads to Increase, Mortality
1752 Decrease, Oogenesis leads to Decrease, Fecundity
1753 Decrease, Ovulation leads to Decrease, Fecundity
1754 Increase, ROS production leads to Increase, Uncoupling of OXPHOS
1755 Blockade, L-Type Calcium Channels leads to Decrease, Calcium currents
1756 Decrease, Calcium currents leads to Decrease, Calcium binding to Troponin C
1757 Decrease, Calcium binding to Troponin C leads to Decrease, Cardiac contractility
1758 Decrease, Cardiac contractility leads to Decrease, Cardiac ejection fraction
1759 Decrease, Cardiac ejection fraction leads to Heart failure
1760 Decrease, Calcium currents leads to Disruption, Intracellular calcium mobilization
1761 Disruption, Intracellular calcium mobilization leads to Disruption, Sarcomere assembly
1762 Disruption, Sarcomere assembly leads to Decrease, Cardiac contractility
1763 Tissue resident cell activation leads to Increased pro-inflammatory mediators
1764 Increased pro-inflammatory mediators leads to Activation, Stellate cells
1765 Binding, SH/SeH proteins involved in protection against oxidative stress leads to Protection against oxidative stress, decreased
1766 Protection against oxidative stress, decreased leads to Oxidative Stress
1767 Inhibition, Aromatase leads to Altered regulation, Alpha hemoglobin
1768 TH synthesis, Decreased leads to Reduction, Plasma 17beta-estradiol concentrations
1769 Reduction, Plasma vitellogenin concentrations leads to Reduction, Cumulative fecundity and spawning
1770 Respiratory irritability leads to Increased Airway Hyper-responsiveness,Cough, Dyspnea
1771 Increased Airway Hyper-responsiveness,Cough, Dyspnea leads to Respiratory irritability
1772 SP (Substance P) release, Local increase of SP leads to Respiratory irritability
1773 Increased NKA leads to Respiratory irritability
1774 Irritation induced sneezing leads to Increased Airway Hyper-responsiveness,Cough, Dyspnea
1775 endocytosis leads to Disruption, Lysosome
1776 Cell injury/death leads to Increased pro-inflammatory mediators
1777 Increased pro-inflammatory mediators leads to Leukocyte recruitment/activation
1778 Leukocyte recruitment/activation leads to Activation, Stellate cells
1779 EMT leads to Collagen Deposition
1780 Mitochondrial Complex I inhibition leads to Decrease in mitochondrial oxidative phosphorylation
1781 Mitochondrial Complex III inhibition leads to Decrease in mitochondrial oxidative phosphorylation
1782 Mitochondrial Complex IV inhibition leads to Decrease in mitochondrial oxidative phosphorylation
1783 Mitochondrial Complex V inhibition leads to Decrease in mitochondrial oxidative phosphorylation
1784 Mitochondrial Complex III inhibition leads to Increased reactive oxygen species (in the mitochondria)
1785 Mitochondrial Complex IV inhibition leads to Increased reactive oxygen species (in the mitochondria)
1786 Mitochondrial Complex V inhibition leads to Increased reactive oxygen species (in the mitochondria)
1787 Decrease in mitochondrial oxidative phosphorylation leads to Mitochondrial Injury
1788 Increased reactive oxygen species (in the mitochondria) leads to Mitochondrial Injury
1789 Necrotic Tissue leads to Liver Injury
1790 Mitochondrial Complex I inhibition leads to Increased reactive oxygen species (in the mitochondria)
1791 Ionizing Energy leads to DNA DNA double strand breaks
1792 DNA DNA double strand breaks leads to DNA repair
1793 DNA repair leads to Increase mutations
1794 DNA repair leads to Increase chromosomal aberrations
1795 Increase mutations leads to Increase cell proliferation
1796 Increase chromosomal aberrations leads to Increase cell proliferation
1797 Increase cell proliferation leads to Increase, lung cancer
1798 Ionizing Energy leads to Increase mutations
1799 Ionizing Energy leads to Increase chromosomal aberrations
1800 Increase mutations leads to Increase, lung cancer
1801 Increase chromosomal aberrations leads to Increase, lung cancer
1802 Histone deacetylase inhibition leads to Reduced neural crest cell migration
1803 Reduced neural crest cell migration leads to Reduced collagen production
1804 Reduced collagen production leads to Smaller and morphologically distorted facial cartilage structures
1805 Histone deacetylase inhibition leads to Reduced collagen production
1806 Histone acetylation, increase leads to Altered, Gene Expression
1807 Altered, Gene Expression leads to Altered differentiation
1808 Altered differentiation leads to Neural tube defects
1809 Inhibition, NADH-ubiquinone oxidoreductase (complex I) leads to Decrease, OXPHOS
1810 Decrease, OXPHOS leads to Decreased Na/K ATPase activity
1811 Decreased Na/K ATPase activity leads to Decreased proximal tubular vectorial transport
1812 Decreased proximal tubular vectorial transport leads to Chemical induced Fanconi syndrome
1813 Blocking of IL-1R leads to Impaired IL-1 signaling
1814 Decreased IL-1 production leads to Impaired IL-1 signaling
1815 Impaired IL-1 signaling leads to Suppressed AP-1
1816 Impaired IL-1 signaling leads to Suppressed NF-kB
1817 Suppressed AP-1 leads to Suppressed DC activation
1818 Suppressed NF-kB leads to Suppressed DC activation
1819 Suppressed DC activation leads to Impaired antigen presentation
1820 Impaired antigen presentation leads to Impaired T cell activation
1821 Impaired T cell activation leads to Suppression, Suppression of T-cell dependent antibody response (TDAR)
1822 Impaired T cell activation leads to Increase, Increased susceptibility to infection
1823 Suppression, Suppression of T-cell dependent antibody response (TDAR) leads to Increase, Increased susceptibility to infection
1824 Decreased IL-1 production leads to Suppressed MyD88
1825 Impaired IL-1 signaling leads to Suppressed MyD88
1826 Suppressed MyD88 leads to Increase, Increased susceptibility to infection
1827 Inhibition, IKK complex leads to Inhibition, Nuclear factor kappa B (NF-kB)
1828 Inhibition, Nuclear factor kappa B (NF-kB) leads to Activation, Caspase 8 pathway
1829 Activation, Caspase 8 pathway leads to Cell injury/death
1830 Cell injury/death leads to Necrotic Tissue
1831 Cell injury/death leads to Activation, Tissue resident cells (Kuppfer cells)
1832 Activation, Tissue resident cells (Kuppfer cells) leads to Increase, proinflammatory mediators (TNFalpha)
1833 Binding of MSAs to microtubules leads to Disturbance in microtubule dynamic instability
1834 Disturbance in microtubule dynamic instability leads to Impaired axonial transport
1835 Impaired axonial transport leads to Sensory axonal peripheral neuropathy
1836 Interaction of α-diketones with arginine residues leads to Proteasomal dysfunction
1837 Proteasomal dysfunction leads to Airway epithelial injury
1838 Airway epithelial injury leads to Increase, Inflammation
1839 Increase, Inflammation leads to Fibroproliferative airway lesions
1840 EMT leads to Fibroproliferative airway lesions
1841 Fibroproliferative airway lesions leads to Bronchiolitis obliterans
1842 Distribution of chemicals leads to Absorption of photon energy
1843 Absorption of photon energy leads to ROS generation
1844 Absorption of photon energy leads to Radical generation
1845 ROS generation leads to Oxidation of membrane lipids
1846 ROS generation leads to Oxidation/denatuation of membrane proteins
1847 ROS generation leads to Oxidation of DNA
1848 Radical generation leads to DNA photo-adducts
1849 Radical generation leads to Protein photo-adducts
1850 Oxidation of membrane lipids leads to Inflammatory events
1851 Oxidation/denatuation of membrane proteins leads to Inflammatory events
1852 Oxidation of DNA leads to Inflammatory events
1853 DNA photo-adducts leads to Inflammatory events
1854 Protein photo-adducts leads to Inflammatory events
1855 Inflammatory events leads to Eczematous eruption
1856 Eczematous eruption leads to Scaling, Lichenification
1857 ACh Synaptic Accumulation leads to Activation, Muscarinic Acetylcholine Receptors
1858 Activation, Muscarinic Acetylcholine Receptors leads to Increased, glutamate
1859 Increased, glutamate leads to Overactivation, NMDARs
1860 Increased, Intracellular Calcium overload leads to Occurrence, Epileptic seizure
1861 Occurrence, Epileptic seizure leads to Increased, glutamate
1862 Increased, Intracellular Calcium overload leads to Cell injury/death
1863 Cell injury/death leads to Neurodegeneration
1864 Inhibition of N-linked glycosylation leads to Accumulation, misfolded proteins
1865 Accumulation, misfolded proteins leads to Unfolded Prortein Response
1866 Unfolded Prortein Response leads to Apoptosis
1867 Apoptosis leads to Activation, hepatic stellate cells
1868 Activation, hepatic stellate cells leads to Liver Injury
1869 Apoptosis leads to Liver Injury
1870 Suppressed MyD88 leads to Inhibition, Nuclear factor kappa B (NF-kB)
1871 Inhibition, Nuclear factor kappa B (NF-kB) leads to Increase, Increased susceptibility to infection
1872 Mitochondrial Complex III inhibition leads to Decrease, OXPHOS
1873 Decrease, Mitochondrial ATP production leads to Increase, Necrosis
1874 Increase, Necrosis leads to Increase, Mortality
1875 Mitochondrial Complex III inhibition leads to Increase, ROS
1876 Increase, ROS leads to Increase,Oxidative DNA damage
1877 Increase,Oxidative DNA damage leads to Increase, Apoptosis
1878 Inhibition of Cyp17A1 activity leads to Reduction, DHEA
1879 Inhibition of Cyp17A1 activity leads to Reduction, androstenedione
1880 5α-reductase, inhibition leads to Decrease, DHT level
1881 Decrease, DHT level leads to Reduction, Plasma 17beta-estradiol concentrations
1882 Reduction, Plasma vitellogenin concentrations leads to Reduction, egg production and spawning
1883 Increase, DNMT inhibition leads to Increase, DNA hypomethylation
1884 Increase, DNA hypomethylation leads to Increase, Gene expression
1885 Increase, Gene expression leads to Decrease, Fecundity
1886 Decrease, Fecundity leads to Decrease, Population trajectory
1887 Increase, DNA hypomethylation leads to Decrease, Transgenerational DNA methylation
1888 Decrease, Transgenerational DNA methylation leads to Increase, Gene expression
1889 Activation, Muscarinic Acetylcholine Receptors leads to Occurrence, Focal Seizure
1890 Occurrence, Focal Seizure leads to Increased, glutamate
1891 tyrosinase leads to Reduction of L-Dopaquinone
1892 Reduction of L-Dopaquinone leads to Reduction in melanin level
1893 Reduction in melanin level leads to Reduction of melanosome level
1894 Reduction of melanosome level leads to Reduction fo Pigmentation pattern
1895 Reduction fo Pigmentation pattern leads to Decrease, Population trajectory
1896 Increase, Mutations leads to Increase, Cell Proliferation (Epithelial Cells)
1897 Increase, DNA Damage leads to Increase, Mutations
1898 Increase, DNA Damage leads to Tissue resident cell activation
1899 Increase, DNA Damage leads to Increase mutations
1900 Increase mutations leads to Increase, Cell Proliferation (Epithelial Cells)
1901 Leukocyte recruitment/activation leads to Increase, Cell Proliferation (Epithelial Cells)
1902 Increased pro-inflammatory mediators leads to N/A, Breast Cancer
1903 Increased pro-inflammatory mediators leads to Increase in RONS
1904 Increase in RONS leads to Increase, DNA Damage
1905 Leukocyte recruitment/activation leads to Increase in RONS
1906 Increase in RONS leads to Tissue resident cell activation
1907 Increase, Cell Proliferation (Epithelial Cells) leads to Increase, Mutations
1908 Increased pro-inflammatory mediators leads to Increase, Cell Proliferation (Epithelial Cells)
1909 Increase, Oxidative DNA damage leads to N/A, Inadequate DNA repair
1910 N/A, Inadequate DNA repair leads to Increase, DNA strand breaks
1911 Increase, DNA strand breaks leads to N/A, Inadequate DNA repair
1912 N/A, Inadequate DNA repair leads to Increase, Chromosomal aberrations
1913 Increase, Oxidative DNA damage leads to Increase, DNA strand breaks
1914 Increase, Oxidative DNA damage leads to Increase, Mutations
1915 Retinaldehyde dehydrogenase leads to retinoic acid
1916 retinoic acid leads to plasma retionic acid
1917 plasma retionic acid leads to Optical elements of the eye
1918 Optical elements of the eye leads to Visual impairment
1919 Visual impairment leads to Decline, Population
1920 Impaired IL-1 signaling leads to Inhibition, Nuclear factor kappa B (NF-kB)
1921 Inhibition, Nuclear factor kappa B (NF-kB) leads to Impaired T cell activation
1922 Impaired T cell activation leads to Impaired Ab production
1923 Impaired Ab production leads to Increase, Increased susceptibility to infection
1924 Wnt ligand stimulation leads to Frizzled activation
1925 Frizzled activation leads to GSK3beta inactivation
1926 GSK3beta inactivation leads to β-catenin activation
1927 β-catenin activation leads to Snail, Zeb, Twist activation
1928 Snail, Zeb, Twist activation leads to Epithelial-mesenchymal transition
1929 Epithelial-mesenchymal transition leads to Resistant gastric cancer
1930 Increase, SAM depletion leads to Increase, DNA hypomethylation
1931 Increase, DNA strand breaks leads to Increase, Mutations
1932 Reduction, DHEA leads to Decrease, testosterone level
1933 Reduction, androstenedione leads to Decrease, testosterone level
1934 Decrease, testosterone level leads to Decrease, DHT level
1935 Decrease, DHT level leads to Decrease, AR activation
1936 Decrease, testosterone level leads to Decrease, AR activation
1937 Decrease, AR activation leads to Impaired inguinoscrotal phase
1938 Impaired inguinoscrotal phase leads to Malformation, cryptorchidism
1939 Increase, DNA strand breaks leads to Increase, Chromosomal aberrations
1940 Inhibition, NADH-ubiquinone oxidoreductase (complex I) leads to Decrease in mitochondrial oxidative phosphorylation
1941 Mitochondrial Injury leads to Increased reactive oxygen species (in the mitochondria)
1942 Mitochondrial Injury leads to Impaired, Proteostasis
1943 Impaired, Proteostasis leads to Cell injury/death
1944 Binding of inhibitor, mitochondrial complex III leads to Mitochondrial Complex III inhibition
1945 Binding of inhibitor, mitochondrial complex IV leads to Mitochondrial Complex IV inhibition
1946 Binding of inhibitor, mitochondrial complex V leads to Mitochondrial Complex V inhibition
1947 TR Antagnoism leads to Hippocampal gene expression, Altered
1948 TR Antagnoism leads to Cognitive Function, Decreased
1949 CBS inhibition leads to Homocysteine increases
1950 MTHFR inhibition leads to Homocysteine increases
1951 Methionine synthase leads to Homocysteine increases
1952 betaine-homocysteine methyltransferase inhibition leads to Homocysteine increases
1953 Homocysteine increases leads to plasma homocysteine increases
1954 plasma homocysteine increases leads to brain Homocysteine level increases
1955 brain Homocysteine level increases leads to Neuronal dysfunctions induction
1956 Decrease in mitochondrial oxidative phosphorylation leads to N/A, Mitochondrial dysfunction 1
1957 Increased reactive oxygen species (in the mitochondria) leads to N/A, Mitochondrial dysfunction 1
1958 N/A, Mitochondrial dysfunction 1 leads to Increased reactive oxygen species (in the mitochondria)
1959 Homocysteine increases leads to Plasma HCY level
1960 Plasma HCY level leads to dysfunction of microcirculation
1961 dysfunction of microcirculation leads to anterior-posterior axis development
1962 Frustrated phagoytosis leads to Release, Cytokine
1963 Release, Cytokine leads to Recruitment of inflammatory cells
1964 Recruitment of inflammatory cells leads to Increased, Reactive oxygen species
1965 Increased, Reactive oxygen species leads to Increased, DNA damage and mutation
1966 Increased, DNA damage and mutation leads to Increase, Cell Proliferation
1967 Increase, Cell Proliferation leads to Lung cancer
1968 Substance - LS interaction leads to Disruption of LS function.
1969 Disruption of LS function. leads to Alveolar collapse
1970 Alveolar collapse leads to Alveolar reopening
1971 Alveolar reopening leads to Loss of barrier function
1972 Loss of barrier function leads to Blood extravasation into the lungs
1973 Blood extravasation into the lungs leads to Acute inhalation toxicity
1974 Alveolar collapse leads to Reduced lung volume
1975 Reduced lung volume leads to Impaired oxygenation of the blood
1976 Impaired oxygenation of the blood leads to Acute inhalation toxicity
1977 Energy Deposition leads to Increase, DNA strand breaks
1978 Increase, Mutations leads to Increase, Cell Proliferation
1979 Increase, Chromosomal aberrations leads to Increase, Cell Proliferation
1980 Increase, Cell Proliferation leads to Increase, lung cancer
1981 Energy Deposition leads to Increase, Mutations
1982 Energy Deposition leads to Increase, Chromosomal aberrations
1983 Energy Deposition leads to Increase, lung cancer
1984 Increase, Mutations leads to Increase, lung cancer
1985 Increase, Chromosomal aberrations leads to Increase, lung cancer
1986 Antagonism,LH receptor leads to Reduction, Progesterone synthesis
1987 Reduction, Progesterone synthesis leads to Reduction, Plasma progesterone concentration
1988 Reduction, Plasma progesterone concentration leads to Reduction, progesterone uptake, decresed maturation
1989 Reduction, progesterone uptake, decresed maturation leads to Impaired ovulation
1990 Impaired ovulation leads to Decrease of egg production and cummulative fecundity
1991 Decrease of egg production and cummulative fecundity leads to Decline, Population trajectory
1992 Activation, AhR leads to Increase, DNMT expression
1993 Increase, DNMT expression leads to Increase, hypermethylation of the promotor region of GnRHR
1994 Increase, hypermethylation of the promotor region of GnRHR leads to Decease, expression of GnRHR
1995 Decease, expression of GnRHR leads to Reduction, 17beta-estradiol synthesis by ovarian granulosa cells
1996 dimerization, AHR/ARNT leads to Increase, DNMT expression
1997 Histone acetylation, increase leads to Cell cycle, disrupted
1998 Occurrence, Focal Seizure leads to Overactivation, NMDARs
1999 Occurrence, Epileptic seizure leads to Overactivation, NMDARs
2000 Inhibition of IL-1 binding to IL-1 receptor leads to Suppression of T cell activation
2001 Suppression of T cell activation leads to Inhibition, Nuclear factor kappa B (NF-kB)
2002 Inhibition of IL-1 binding to IL-1 receptor leads to Inhibition, Nuclear factor kappa B (NF-kB)
2003 Inhibition, Nuclear factor kappa B (NF-kB) leads to Suppression of T cell activation
2004 Suppression of T cell activation leads to Increase, Increased susceptibility to infection
2005 Increased Cholinergic Signaling leads to Cardiovascular dysregulation
2006 Cardiovascular dysregulation leads to Respiratory distress/arrest
2007 AchE Inhibition leads to Cardiovascular dysregulation
2008 Oxidative Stress leads to Wnt ligand stimulation
2009 Increased, Reactive oxygen species leads to Oxidative Stress
2010 Histone deacetylase inhibition leads to Spermatocyte depletion
2011 Increased Cholinergic Signaling leads to Impaired coordination and movement
2012 Impaired coordination and movement leads to Increased Mortality
2013 Increased Mortality leads to Decrease, Population trajectory
2014 AchE Inhibition leads to Impaired coordination and movement
2015 Impaired coordination and movement leads to Decrease, Population trajectory
2016 AchE Inhibition leads to Decrease, Population trajectory
2017 Stimulation of TLR7/8 leads to Overproduction of IL-23
2018 Overproduction of IL-23 leads to Overproduction of IL-17
2019 Overproduction of IL-17 leads to Skin disease
2020 Binding to estrogen receptor (ER)-α leads to Induction of GATA3 expression
2021 Induction of GATA3 expression leads to Increase of Th2 cells producing IL-4
2022 Increase of Th2 cells producing IL-4 leads to Increase of autoantibody production
2023 Increase of autoantibody production leads to Exacerbation of SLE
2024 Inhibition of JAK3 leads to STAT5 inhibition
2025 STAT5 inhibition leads to Suppression of STAT5 binding
2026 Suppression of STAT5 binding leads to Suppression of IL-4 production
2027 Suppression of IL-4 production leads to Impairment, TDAR
2028 Inhibition, trypsin leads to Increased monitor peptide
2029 Increased monitor peptide leads to Increased blood CCK level
2030 Increased blood CCK level leads to Increased acinar cell exocrine secretion
2031 Increased acinar cell exocrine secretion leads to Acinar cell proliferation
2032 Acinar cell proliferation leads to Acinar cell tumors
2033 Increased, Reactive oxygen species leads to β-catenin activation
2034 test leads to Unknown, MIE
2035 Unknown, MIE leads to Unknown,
2036 Unknown, MIE leads to N/A, Unknown
2037 test leads to N/A, Unknown
2038 T4 in serum, Decreased leads to Decreased, Triiodothyronine (T3) in serum
2039 Activation, Glucocorticoid Receptor leads to Decreased, Mitochondrial Fatty Acid Beta Oxidation
2040 Decreased, Mitochondrial Fatty Acid Beta Oxidation leads to Increased, Liver Steatosis
2041 Activation, Glucocorticoid Receptor leads to Decreased, PPAR-alpha activation
2042 Decreased, PPAR-alpha activation leads to Increased, Liver Steatosis
2052 Enhanced viral entry and gene expression leads to Increased proinflammatory mediators
2053 Increased proinflammatory mediators leads to Pro-inflammatory cytokines increased
2056 Binding of S protein to ACE receptor leads to Enhanced viral entry and gene expression
2061 Increased proinflammatory mediators leads to Increase inflammatory immune responses
2062 Increase inflammatory immune responses leads to Increase, the risk of acute respiratory failure
2064 Increase, the risk of acute respiratory failure leads to Decreased mortality
2065 ACE2 inhibition leads to Increases AngII
2066 Increases AngII leads to Increase plasma Ang II
2067 Increase plasma Ang II leads to Increase,collagen synthesis
2068 Increase,collagen synthesis leads to Induction lung fibrosis
2069 Chronic ROS leads to Sustained tissue damage / macrophage activation/ porcupine-induced Wnt secretion
2070 Sustained tissue damage / macrophage activation/ porcupine-induced Wnt secretion leads to Proliferation/ beta-catenin activation
2071 Proliferation/ beta-catenin activation leads to Epithelial-mesenchymal transition
2072 Decreased, cholesterol leads to Decreased, 11KT
2073 Activation, PPARα leads to Decreased, cholesterol
2074 Increase, DNA strand breaks leads to Increase, Apoptosis
2075 Increase, Apoptosis leads to Reduce, Sperm count
2076 Decreased, 11KT leads to Impaired, Spermatogenesis
2077 Activation, Glucocorticoid Receptor leads to Increase, Cripto-1 expression
2078 Increase, Cripto-1 expression leads to Inhibition, Activin signaling
2079 Inhibition, Activin signaling leads to Inhibition, Fin regeneration
2080 Inhibition, Fin regeneration leads to Reduced, Swimming performance
2081 Reduced, Swimming performance leads to Decrease, Population trajectory
2082 Increase, Cripto-1 expression leads to Inhibition, Fin regeneration
2083 Mitochondrial impairment leads to cell injury
2084 cell injury leads to Increase, Regenerative cell proliferation (urothelial cells)
2085 Increase, Hyperplasia (urothelial) leads to carcinogenicity
2087 Increase, Formation of DNA photoproducts leads to Increase, DNA DSB
2088 Increase, DNA DSB leads to Increase, Apoptosis
2089 Increase, ROS production leads to Increase, Protein oxidation
2090 Increase, Protein oxidation leads to Decrease, Osmoregulation
2091 Decrease, Osmoregulation leads to Increase, Body fluid overload
2092 Increase, Body fluid overload leads to Increase, Mortality
2093 Increase, ROS production leads to Decrease, MMP
2094 Decrease, MMP leads to Decrease, OXPHOS
2095 Decrease, OXPHOS leads to Decrease, ATP production
2096 Decrease, ATP production leads to Increase, Mortality
2097 Increase, LPO leads to Decrease, Neutral lipids
2098 Decrease, Neutral lipids leads to Decrease, ATP production
2099 Increase, ROS production leads to Increase,Oxidative DNA damage
2100 Increase,Oxidative DNA damage leads to Increase, DNA DSB
2101 Increase, DNMT inhibition leads to Decrease, Global DNA methylation
2102 Decrease, Global DNA methylation leads to Increase, Casp transcription
2103 Increase, Casp transcription leads to Increase, Oocyte apoptosis
2104 Increase, Oocyte apoptosis leads to Decrease, Oogenesis
2105 Increase, Casp transcription leads to Increase, Ovarian somatic cell apoptosis
2106 Increase, Ovarian somatic cell apoptosis leads to Increase, Ovarian follicle breakdown
2107 Increase, Ovarian follicle breakdown leads to Decrease, Oogenesis
2108 Increase, DNMT inhibition leads to Increase, DNA DSB
2109 Increase, DNA DSB leads to Increase, Casp transcription
2110 Decrease, Global DNA methylation leads to Decrease, Heritable DNA methylation (F3)
2111 Decrease, Heritable DNA methylation (F3) leads to Increase, Casp transcription (F3)
2112 Increase, Casp transcription (F3) leads to Increase, Oocyte apoptosis (F3)
2113 Increase, Oocyte apoptosis (F3) leads to Decrease, Oogenesis (F3)
2114 Decrease, Oogenesis (F3) leads to Decrease, Fecundity (F3)
2115 Decrease, Fecundity (F3) leads to Decrease, Population trajectory
2116 Increase, Casp transcription (F3) leads to Increase, Ovarian somatic cell apoptosis (F3)
2117 Increase, Ovarian somatic cell apoptosis (F3) leads to Increase, Ovarian follicle breakdown (F3)
2118 Increase, Ovarian follicle breakdown (F3) leads to Decrease, Oogenesis (F3)
2119 Increase, ATP synthase inhibition leads to Decrease, OXPHOS
2120 Decrease, ATP production leads to Increase, Oocyte apoptosis
2121 Decrease, ATP production leads to Increase, Necrosis
2122 Increase, Necrosis leads to Increase, Ovarian follicle breakdown
2123 Antagonism, Androgen receptor leads to short male AGD
2124 Decrease, AR activation leads to Decreased, Transcription of genes by AR
2125 Reduction, Testosterone synthesis in Leydig cells leads to reduction, testosterone levels
2126 reduction, testosterone levels leads to Decrease, DHT level
2127 Decreased, Transcription of genes by AR leads to short male AGD
2128 Decrease, AR activation leads to decrease, transcription of genes by AR
2129 decrease, transcription of genes by AR leads to short male AGD
2130 Antagonism, Androgen receptor leads to Decrease, AR activation
2131 reduction, testosterone levels leads to Decrease, AR activation
2132 Decreased, Transcription of genes by AR leads to nipple retention (NR) male
2133 Antagonism, Androgen receptor leads to nipple retention (NR) male
2134 Activation, PPARα leads to Decreased, 11KT
2135 Increase, the risk of acute respiratory failure leads to Increased Mortality
2136 ACE2 agonism leads to Increase plasma Ang II
2137 ACE2 agonism leads to Increases AngII
2138 Increase plasma Ang II leads to Accumulation, Collagen
2139 Accumulation, Collagen leads to Lung fibrosis
2140 Increased, Intracellular Calcium overload leads to Status epilepticus
2141 Status epilepticus leads to Overactivation, NMDARs
2142 Reduction, Cumulative fecundity and spawning leads to Decline, Population
2143 Visual impairment leads to Decrease, Population trajectory
2144 Inhibition, Aromatase leads to Reduction, E2 Synthesis by the undifferentiated gonad
2145 Reduction, E2 Synthesis by the undifferentiated gonad leads to Increased, Differentiation to Testis
2146 Increased, Differentiation to Testis leads to Increased, Male Biased Sex Ratio
2147 Increased, Male Biased Sex Ratio leads to Decrease, Population trajectory
2148 TLR4 activation leads to Activation, JNK
2149 Activation, JNK leads to AP-1 activation
2150 Activation, JNK leads to Pin-1 activation
2151 Pin-1 activation leads to TGFbeta expression
2152 TGFbeta expression leads to Activation, TGF-beta pathway
2153 Activation, TGF-beta pathway leads to EMT
2154 EMT leads to Pulmonary fibrosis
2155 TLR4 activation leads to Activation, TGF-beta pathway
2156 Inactivation of PPARγ leads to Activation, TGF-beta pathway
2157 AP-1 activation leads to TGFbeta expression
2158 11β-hydroxylase inhibition leads to Decreased, 11KT
2161 Decreased size and sperm volume leads to impaired, Fertility
2162 Inhibition of 11β-HSD leads to Decreased, 11KT
2164 Impaired, Spermatogenesis leads to Decrease, Fertility
2165 Decreased, 11KT leads to Decrease, Fertility
2166 Decreased, 11KT leads to Decreased size and sperm volume
2167 Inhibition, Aromatase leads to Increased, Differentiation to Testis
2168 T4 in serum, Decreased leads to Altered, Amphibian metamorphosis
2169 Decrease, Growth leads to Decrease, Population trajectory
2170 Increase, Chitinase inhibition leads to Decrease, Digestion of old cuticle
2171 Decrease, Digestion of old cuticle leads to Increase, Premature molting
2172 Increase, Chitobiase inhibition leads to Decrease, Digestion of old cuticle
2173 Alveolar reopening leads to Loss of alveolar capillary membrane integrity
2174 Loss of alveolar capillary membrane integrity leads to Blood extravasation into the lungs